<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="hlh" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">hlh</book-part-id>
      <title-group>
        <title>Hemophagocytic Lymphohistiocytosis, Familial</title>
        <alt-title alt-title-type="alt-title">Synonyms: FHLH, Familial Erythrophagocytic Lymphohistiocytosis</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zhang</surname>
            <given-names>Kejian</given-names>
          </name>
          <degrees>MD, MBA</degrees>
          <aff>Associate Professor of Pediatrics, Division of Human Genetics<break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>kejian.zhang@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Filipovich</surname>
            <given-names>Alexandra H</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Professor, Division of Bone Marrow Transplant and Immune Deficiency<break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>lisa.filipovich@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Johnson</surname>
            <given-names>Judith</given-names>
          </name>
          <degrees>MS</degrees>
          <aff>Genetic Counselor and Project Manager<break/>Division of Human Genetics <break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>juditha.johnson@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marsh</surname>
            <given-names>Rebecca A</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Assistant Professor, Division of Bone Marrow Transplant and Immune Deficiency<break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>rebecca.marsh@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Villanueva</surname>
            <given-names>Joyce</given-names>
          </name>
          <degrees>MT, MBA</degrees>
          <aff>Research and Development Coordinator<break/>Immunodeficiency and Histiocytosis Program<break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>joyce.villanueva@cchmc.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2006-03-22" date-type="created">
          <day>22</day>
          <month>3</month>
          <year>2006</year>
        </date>
        <date iso-8601-date="2013-01-17" date-type="updated">
          <day>17</day>
          <month>1</month>
          <year>2013</year>
        </date>
        <date iso-8601-date="2010-09-07" date-type="revised">
          <day>7</day>
          <month>9</month>
          <year>2010</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="hartsfield" document-type="chapter">Hartsfield Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="hemo-a" document-type="chapter">Hemophilia A</related-object>
      <abstract id="hlh.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Familial hemophagocytic lymphohistiocytosis (FHL) is characterized by proliferation and infiltration of hyperactivated macrophages and T-lymphocytes manifesting as acute illness with prolonged fever, cytopenias, and hepatosplenomegaly. Onset is typically within the first months or years of life and, on occasion, in utero, although later childhood or adult onset is more common than previously suspected. Neurologic abnormalities may be present initially or may develop later; they may include increased intracranial pressure, irritability, neck stiffness, hypotonia, hypertonia, convulsions, cranial nerve palsies, ataxia, hemiplegia, quadriplegia, blindness, and coma. Rash and lymphadenopathy are less common. Other findings include liver dysfunction and bone marrow hemophagocytosis. The median survival of children with typical FHL, without treatment, is less than two months; progression of hemophagocytic lymphohistiocytosis and infection account for the majority of deaths in untreated individuals.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of FHL is made based on the presence of clinical criteria and is confirmed by molecular genetic testing. Five disease subtypes (FHL1, FHL2, FHL3, FHL4, and FHL5) are described. Four genes in which pathogenic variants are causative have been identified: <italic toggle="yes">PRF1</italic> (FHL2), <italic toggle="yes">UNC13D</italic> (FHL3), <italic toggle="yes">STX11</italic> (FHL4), and <italic toggle="yes">STXBP2</italic> (FHL5).</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Antibiotics or antiviral agents are used to treat or prevent infections that may have triggered the exaggerated inflammatory response. Individuals suspected of having FHL or diagnosed with FHL are treated with chemotherapy and immunotherapy to achieve clinical stability prior to allogeneic hematopoietic cell transplantation (HCT).</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Allogeneic HCT is the only curative therapy and is undertaken as early in life as feasible in children with confirmed FHL.</p>
          <p><italic toggle="yes">Surveillance</italic>: Following HCT, annual neuropsychological evaluation and regular follow up by a transplant specialist to monitor for late complications related to growth and hormone function is recommended.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Live vaccines; exposure to infections.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Molecular genetic testing of at-risk sibs for the familial pathogenic variants enables consideration of presymptomatic bone marrow transplantation and timely treatment.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>FHL is inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the two pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="hlh.Diagnosis">
        <title>Diagnosis</title>
        <sec id="hlh.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of familial hemophagocytic lymphohistiocytosis (FHL), a cellular immunologic disorder resulting from genetic defects in cytotoxic cell function that lead to hyperactivation, proliferation, and infiltration of macrophages and T-lymphocytes, can be established if <bold>1</bold>
<bold>and/or 2</bold> is present:</p>
          <p><bold>1. Biallelic pathogenic variants</bold> in any one of <italic toggle="yes">PRF1</italic>, <italic toggle="yes">UNC13D</italic> (also known as <italic toggle="yes">MUNC13-4</italic>), <italic toggle="yes">STX11,</italic> or <italic toggle="yes">STXBP2</italic></p>
          <p><bold>2. At least five of the eight following criteria</bold> based on the guidelines of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.histiocytesociety.org/">Histiocyte Society</ext-link> [<xref ref-type="bibr" rid="hlh.REF.henter.2007.124">Henter et al 2007</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Prolonged fever (&#x0003e;7 days)</p>
            </list-item>
            <list-item>
              <p>Cytopenias affecting <bold>two or three</bold> of the three lineages in the peripheral blood:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Hemoglobin &#x0003c;90 g/L (for infants age &#x0003c;4 weeks: Hgb &#x0003c;100 g/L)</p>
                </list-item>
                <list-item>
                  <p>Platelets &#x0003c;100x109/L</p>
                </list-item>
                <list-item>
                  <p>Neutrophils &#x0003c;1.0x109/L</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Splenomegaly</p>
            </list-item>
            <list-item>
              <p>Hypertriglyceridemia and/or hypofibrinogenemia</p>
              <list list-type="bullet">
                <list-item>
                  <p>Fasting triglycerides &#x02265;2.0 mmol/L or &#x0003e;3 SD of the normal value for age</p>
                </list-item>
                <list-item>
                  <p>Fibrinogen &#x02264;1.5 g/L</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Hemophagocytosis. Non-malignant, mixed lymphohistiocytic accumulation in the reticuloendothelial system; the spleen, liver, lymph nodes, bone marrow, and CNS are most frequently involved. Note: (1) Hemophagocytosis may not be apparent early in the course of the disease. (2) Hemophagocytosis is seen less often in the liver, where lymphocytic infiltration of the portal areas is typical [<xref ref-type="bibr" rid="hlh.REF.kapelari.2005.619">Kapelari et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>Low or absent natural killer (NK) cell activity. This is common prior to and during active disease, as well as after remission following chemotherapy in a significant proportion of individuals with FHL. Normal or raised NK cell activity has also been observed in some affected individuals, including those with <italic toggle="yes">UNC13D</italic> pathogenic variants [<xref ref-type="bibr" rid="hlh.REF.yamamoto.2004.763">Yamamoto et al 2004</xref>, <xref ref-type="bibr" rid="hlh.REF.ishii.2005.3442">Ishii et al 2005</xref>]. Note: (1) NK cell activity normative values are per local laboratory reference. (2) The number of circulating NK cells (CD56+/16+) is generally within normal limits. (3) In secondary (acquired or reactive) hemophagocytic lymphohistiocytosis (HLH), NK cell activity has been reported to normalize during remission [<xref ref-type="bibr" rid="hlh.REF.horne.2005b.658">Horne et al 2005b</xref>, <xref ref-type="bibr" rid="hlh.REF.ishii.2005.3442">Ishii et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>Hyperferritinemia. Serum ferritin concentration &#x02265;500 &#x000b5;g/L (normal 10-290 &#x000b5;g/L)</p>
            </list-item>
            <list-item>
              <p>High plasma concentrations of soluble CD25 (soluble IL2R&#x003b1;); &#x02265;2400 U/mLNote: (1) Normal range depends on test methodology used. (2) Results must be compared to age-matched controls.</p>
            </list-item>
          </list>
          <p>The presence of inflammatory cells in the spinal fluid in association with increased CSF protein and/or characteristic findings on brain MRI (including gross demyelination or failure of normal myelination during the first year of life, multifocal inflammation involving gray and white matter and intracranial bleeding, generalized atrophy, or brain edema are also highly suspicious for HLH [<xref ref-type="bibr" rid="hlh.REF.filipovich.2011.512">Filipovich 2011</xref>] but are not part of the formal diagnostic criteria.</p>
          <p>In addition, a positive family history of affected sibs and/or parental consanguinity in a symptomatic individual supports the diagnosis of FHL.</p>
        </sec>
        <sec id="hlh.Testing">
          <title>Testing</title>
          <p>
            <bold>Protein analysis</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Perforin (the protein product of <italic toggle="yes">PRF1</italic>) analysis by flow cytometry:</p>
              <list list-type="bullet">
                <list-item>
                  <p>In general, absent or markedly decreased perforin protein expression is highly likely to be associated with homozygous or compound heterozygous pathogenic variants in <italic toggle="yes">PRF1</italic>.</p>
                </list-item>
                <list-item>
                  <p>Of note, normal perforin protein expression may be associated with <italic toggle="yes">PRF1</italic> pathogenic variants because some missense variants alter perforin protein function without significantly changing protein expression.</p>
                </list-item>
                <list-item>
                  <p>If perforin protein expression is normal or increased, <italic toggle="yes">UNC13D</italic> or <italic toggle="yes">STXBP2</italic> molecular genetic testing should be considered first.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Natural killer (NK) cell activity analysis:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Low or absent NK cell activity is an important biomarker in persons with FHL.</p>
                </list-item>
                <list-item>
                  <p>Low or absent NK cell activity is usually observed in persons with confirmed biallelic pathogenic variants in <italic toggle="yes">PRF1</italic>, <italic toggle="yes">UNC13D</italic>, <italic toggle="yes">STXBP2</italic> or <italic toggle="yes">STX11</italic> [<xref ref-type="bibr" rid="hlh.REF.sieni.2012a.29">Sieni et al 2012a</xref>].</p>
                </list-item>
                <list-item>
                  <p>In secondary (acquired or reactive) hemophagocytic lymphohistiocytosis (HLH), NK cell activity may fluctuate over time [<xref ref-type="bibr" rid="hlh.REF.horne.2005b.658">Horne et al 2005b</xref>, <xref ref-type="bibr" rid="hlh.REF.ishii.2005.3442">Ishii et al 2005</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>NK cell degranulation (CD107a) analysis:</p>
              <list list-type="bullet">
                <list-item>
                  <p>NK cell degranulation can be quantified by measurement of upregulation of surface CD107a [<xref ref-type="bibr" rid="hlh.REF.bryceson.2007.1906">Bryceson et al 2007</xref>].</p>
                </list-item>
                <list-item>
                  <p>Defective CD107a surface expression in NK cells is a frequent finding in persons with <italic toggle="yes">UNC13D</italic> pathogenic variants (FHL3) and <italic toggle="yes">STX11</italic> pathogenic variants (FHL4), in contrast to healthy controls or persons with <italic toggle="yes">PRF1</italic> pathogenic variants (FHL2) [<xref ref-type="bibr" rid="hlh.REF.marcenaro.2006.2316">Marcenaro et al 2006</xref>]. Individuals with pathogenic variants in <italic toggle="yes">STXBP2</italic> (FHL5) also have defective CD107a expression [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Granzyme B initiates caspase-dependent and caspase-independent apoptotic killing of target cells.</p>
              <list list-type="bullet">
                <list-item>
                  <p>In most types of HLH, including those caused by mutation of <italic toggle="yes">PRF1</italic> and <italic toggle="yes">UNC13D</italic> as well as secondary HLH, granzyme B ranges from increased to markedly increased.</p>
                </list-item>
                <list-item>
                  <p>Increased amounts of granzyme B in persons with HLH do not necessarily indicate normal killing, but most likely indicate that the granules housing the granzymes are not able to mobilize normally.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Soluble IL2R is an indicator of prolonged activation of T cells.</p>
              <list list-type="bullet">
                <list-item>
                  <p>As the IL-2 receptor (CD25) forms on the surface of T cells during activation, increasing density of the receptor causes shedding into the plasma.</p>
                </list-item>
                <list-item>
                  <p>This soluble form of the receptor is useful as a diagnostic criterion of any of the forms of HLH and for monitoring reoccurrence of the disease.</p>
                </list-item>
                <list-item>
                  <p>Elevated soluble IL-2 receptor levels do not differentiate between primary (genetic) and secondary HLH.</p>
                </list-item>
                <list-item>
                  <p>It is expected for children to have different expression of CD25 and thus the soluble form of the IL2R in plasma at different ages. Therefore, when interpreting results in children, age-based reference ranges should be used.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Serum ferritin concentration is a marker for generalized inflammation.</p>
              <list list-type="bullet">
                <list-item>
                  <p>It is, however, markedly elevated in the majority of persons with HLH and is a very sensitive indicator of HLH when serum concentrations are markedly increased.</p>
                </list-item>
                <list-item>
                  <p>Increased serum ferritin concentrations make no distinction between genetic and secondary HLH.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <sec id="hlh.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Genes/loci.</bold> Five loci (FHL1, FHL2, FHL3, FHL4, and FHL5) are associated with familial hemophagocytic lymphohistiocytosis; the five disease subtypes are based on these loci (<xref ref-type="table" rid="hlh.T.locus_names_genes_and_pathogenic_v">Table 1</xref>). Four genes have been identified and characterized: <italic toggle="yes">PRF1</italic> (FHL2), <italic toggle="yes">UNC13D</italic> (FHL3), <italic toggle="yes">STX11</italic> (FHL4), and <italic toggle="yes">STXBP2</italic> (FHL5).</p>
            <table-wrap id="hlh.T.locus_names_genes_and_pathogenic_v" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Locus Names, Genes, and Pathogenic Variants Associated with Familial Hemophagocytic Lymphohistiocytosis</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Locus Name</th>
                    <th id="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene</th>
                    <th id="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of FHL</th>
                    <th id="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Identified</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">FHL1</td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">N/A</td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Four consanguineous Pakistani families&#x000a0;<sup>1</sup></td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">N/A</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">FHL2</td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">PRF1</italic>
                    </td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">20%-30%&#x000a0;<sup>2,&#x000a0;3</sup> worldwide<break/>&#x0003e;50% in African American families&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Multiple distinctive pathogenic variants throughout the entire coding region</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">FHL3</td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">UNC13D</italic><break/>(<italic toggle="yes">MUNC13-4</italic>)</td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~20%-30%&#x000a0;<sup>3,&#x000a0;5</sup> worldwide</td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Multiple distinctive pathogenic variants throughout the entire coding region and splicing sites<break/>Deep intronic pathogenic variant and large inversion also reported&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">FHL4</td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">STX11</italic>
                    </td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~20% of Turkish/Kurdish families&#x000a0;<sup>5,&#x000a0;7</sup>
<break/>Biallelic pathogenic variants identified in other ethnic groups, albeit at a low frequency&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Three recurrent pathogenic variants identified in Turkish/Kurdish families<break/>Additional pathogenic variants identified in other populations</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">FHL5</td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">STXBP2</italic>
                    </td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">16% in Central Europeans, Turks, and Saudis&#x000a0;<sup>9</sup><break/>~20% in North Americans with FHL&#x000a0;<sup>10</sup></td>
                    <td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Multiple distinctive pathogenic variants throughout the entire coding region and splicing sites</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="hlh.TF.1.1">
                  <label>1. </label>
                  <p>Linkage analysis using homozygosity mapping in four consanguineous families of Pakistani descent with hemophagocytic lymphohistiocytosis (HLH) identified a locus (FHL1) on chromosome 9q21.3 22 [<xref ref-type="bibr" rid="hlh.REF.ohadi.1999.165">Ohadi et al 1999</xref>]. No gene in which mutation is causative has been identified at this locus.</p>
                </fn>
                <fn id="hlh.TF.1.2">
                  <label>2. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.voskoboinik.2004.811">Voskoboinik et al [2004]</xref>
                  </p>
                </fn>
                <fn id="hlh.TF.1.3">
                  <label>3. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.ishii.2005.3442">Ishii et al [2005]</xref>
                  </p>
                </fn>
                <fn id="hlh.TF.1.4">
                  <label>4. </label>
                  <p><xref ref-type="bibr" rid="hlh.REF.molleran_lee.2004.137">Molleran Lee et al [2004]</xref>, <xref ref-type="bibr" rid="hlh.REF.lee.2006.134">Lee et al [2006]</xref></p>
                </fn>
                <fn id="hlh.TF.1.5">
                  <label>5. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.zur_stadt.2005.827">zur Stadt et al [2005]</xref>
                  </p>
                </fn>
                <fn id="hlh.TF.1.6">
                  <label>6. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.meeths.2011.5783">Meeths et al [2011]</xref>
                  </p>
                </fn>
                <fn id="hlh.TF.1.7">
                  <label>7. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.zur_stadt.2006.62">zur Stadt et al [2006]</xref>
                  </p>
                </fn>
                <fn id="hlh.TF.1.8">
                  <label>8. </label>
                  <p><xref ref-type="bibr" rid="hlh.REF.marsh.2010b.134">Marsh et al [2010b]</xref>; Weitzman, personal communication (2010)</p>
                </fn>
                <fn id="hlh.TF.1.9">
                  <label>9. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.zur_stadt.2009.482">zur Stadt et al [2009]</xref>
                  </p>
                </fn>
                <fn id="hlh.TF.1.10">
                  <label>10. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.johnson.2010">Johnson et al [2010]</xref>
                  </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Evidence for locus heterogeneity.</bold> Approximately 30% of individuals diagnosed with FHL do not have identified pathogenic variants in any of the four genes listed (see <xref ref-type="table" rid="hlh.T.locus_names_genes_and_pathogenic_v">Table 1</xref>). <xref ref-type="bibr" rid="hlh.REF.m_nasch_.2005.165">M&#x000e9;nasch&#x000e9; et al [2005]</xref> provide evidence that additional genetic loci may be responsible for FHL.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="hlh.T.summary_of_molecular_genetic_testi" position="anchor" orientation="portrait">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Familial Hemophagocytic Lymphohistiocytosis</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Locus Name / Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of FHL Attributed to Pathogenic Variants in This Gene</th>
                    <th id="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>2</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">FHL2<break/>/ <italic toggle="yes">PRF1</italic></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">20%-30%&#x000a0;<sup>3</sup><break/>&#x0003e;50%&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">FHL3<break/>/ <italic toggle="yes">UNC13D</italic></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">20%-30%&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>7,&#x000a0;8</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Unknown</td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">253-kb inversion&#x000a0;<sup>9</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">FHL4<break/>/ <italic toggle="yes">STX11</italic></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~20% in Turks/Kurds&#x000a0;<sup>10</sup><break/>1% in North Americans&#x000a0;<sup>11</sup><break/>5% in Central Europeans&#x000a0;<sup>10</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Unknown</td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Deletion / duplication analysis&#x000a0;<sup>12</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Exon and whole-gene deletion&#x000a0;<sup>13</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">FHL5<break/>/ <italic toggle="yes">STXBP2</italic></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~20% in North Americans&#x000a0;<sup>14</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_hlh.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>7</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="hlh.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="hlh" object-id="hlh.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="hlh.TF.2.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="hlh.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="hlh.TF.2.3">
                  <label>3. </label>
                  <p>Pathogenic variants in both <italic toggle="yes">PRF1</italic> and <italic toggle="yes">UNC13D</italic> have been identified with almost equal frequency (~20%-30%) in individuals of western European and Japanese descent [<xref ref-type="bibr" rid="hlh.REF.g_ransdotter_ericson.2001.590">G&#x000f6;ransdotter Ericson et al 2001</xref>, <xref ref-type="bibr" rid="hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</xref>, <xref ref-type="bibr" rid="hlh.REF.ishii.2005.3442">Ishii et al 2005</xref>, <xref ref-type="bibr" rid="hlh.REF.lee.2006.134">Lee et al 2006</xref>].</p>
                </fn>
                <fn id="hlh.TF.2.4">
                  <label>4. </label>
                  <p>For individuals of African American descent [<xref ref-type="bibr" rid="hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</xref>]</p>
                </fn>
                <fn id="hlh.TF.2.5">
                  <label>5. </label>
                  <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="hlh.TF.2.6">
                  <label>6. </label>
                  <p>Sequence analysis and scanning of the entire gene for pathogenic variants can have similar variant detection frequencies; however, variant detection rates for scanning may vary considerably between laboratories depending on the specific protocol used.</p>
                </fn>
                <fn id="hlh.TF.2.7">
                  <label>7. </label>
                  <p>Single pathogenic variants have been identified in <italic toggle="yes">PRF1</italic> [Johnson, unpublished data (2012)], <italic toggle="yes">UNC13D</italic> [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2005.827">zur Stadt et al 2005</xref>; Qian, personal communication (2012)], and <italic toggle="yes">STXBP2</italic> [Johnson, unpublished (2012)] in a minority of individuals with HLH. These data suggest that a second pathogenic variant in (a) the other allele not detectable by direct sequencing, or in (b) a different HLH-related gene may be responsible for a minority of cases. Based on family studies, there is no evidence of a dominant model of disease in FHL2, FHL3, FHL4, or FHL5.</p>
                </fn>
                <fn id="hlh.TF.2.8">
                  <label>8. </label>
                  <p>A deep intronic pathogenic variant has been reported; this must be included in design of sequence analysis approach (see <xref ref-type="sec" rid="hlh.Molecular_Genetics">Molecular Genetics</xref>) [<xref ref-type="bibr" rid="hlh.REF.meeths.2011.5783">Meeths et al 2011</xref>].</p>
                </fn>
                <fn id="hlh.TF.2.9">
                  <label>9. </label>
                  <p>Targeted PCR specific for the breakpoints of the 253-kb inversion (see <xref ref-type="sec" rid="hlh.Molecular_Genetics">Molecular Genetics</xref>) [<xref ref-type="bibr" rid="hlh.REF.meeths.2011.5783">Meeths et al 2011</xref>]</p>
                </fn>
                <fn id="hlh.TF.2.10">
                  <label>10. </label>
                  <p><xref ref-type="bibr" rid="hlh.REF.rudd.2006.e14">Rudd et al [2006]</xref>, <xref ref-type="bibr" rid="hlh.REF.zur_stadt.2006.62">zur Stadt et al [2006]</xref></p>
                </fn>
                <fn id="hlh.TF.2.11">
                  <label>11. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.marsh.2010a.1079">Marsh et al [2010a]</xref>
                  </p>
                </fn>
                <fn id="hlh.TF.2.12">
                  <label>12. </label>
                  <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="hlh.TF.2.13">
                  <label>13. </label>
                  <p>A whole-gene deletion in <italic toggle="yes">STX11</italic> has been reported [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2005.827">zur Stadt et al 2005</xref>].</p>
                </fn>
                <fn id="hlh.TF.2.14">
                  <label>14. </label>
                  <p>
                    <xref ref-type="bibr" rid="hlh.REF.johnson.2010">Johnson et al [2010]</xref>
                  </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p>
              <bold>Interpretation of test results</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Some individuals with FHL have only one identified pathogenic variant; it is possible that the second allele is mutated in the promoter region, deeper in the introns in other non-coding regions of the gene, or is a large complex rearrangement and is thus undetectable by methods in current use. Alternately, a second pathogenic variant could be present in a different HLH-related gene for which clinical testing is not currently possible.</p>
              </list-item>
              <list-item>
                <p>Approximately 30% of North American individuals with FHL do not have pathogenic variants in <italic toggle="yes">PRF1</italic>, <italic toggle="yes">UNC13D</italic>, <italic toggle="yes">STX11</italic> or <italic toggle="yes">STXBP2</italic> [Johnson, unpublished data (2012)]; therefore, normal test results do not exclude the diagnosis of FHL.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="hlh.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> The recommended genetic workup of a person with HLH is complex and depends on the individual&#x02019;s race/ethnicity, immunologic test results, and clinical presentation, among other factors (see <xref ref-type="sec" rid="hlh.GenotypePhenotype_Correlations">Genotype/Phenotype Correlations</xref>). A <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cincinnatichildrens.org/service/h/hlh/clinical/test/">testing algorithm</ext-link> is available to assist clinicians in the prioritization of testing [<xref ref-type="bibr" rid="hlh.REF.jordan.2011.4041">Jordan et al 2011</xref>].</p>
          <p>No unique clinical findings distinguish between FHL2, FHL3, FHL4, and FHL5. However, immunologic testing may be useful in directing the genetic workup of a person with FLH (see <xref ref-type="sec" rid="hlh.GenotypePhenotype_Correlations">Genotype/Phenotype Correlations</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cincinnatichildrens.org/service/h/hlh/clinical/test/">testing algorithm</ext-link>).</p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">PRF1</italic> sequence analysis / scanning for pathogenic variants is generally performed first, as more than 80% of African Americans and 20% of North Americans of northern European background with FHL have at least one <italic toggle="yes">PRF1</italic> pathogenic variant [Johnson, unpublished data (2012)].</p>
              <list list-type="bullet">
                <list-item>
                  <p>Sequence analysis typically does not detect gross deletions (exon, multiexon, or whole-gene deletions), insertions, or some complex gene rearrangements. However, no gross deletions, insertions, or complex gene rearrangements have been identified in <italic toggle="yes">PRF1</italic> to date.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In persons of northern European background, <italic toggle="yes">UNC13D</italic> molecular genetic testing is generally performed next. <italic toggle="yes">UNC13D</italic> pathogenic variants are rare in African Americans. Sequencing of the entire coding region and exon/intron boundaries of <italic toggle="yes">UND13D</italic> including targeted analyses of the deep intronic splicing variant and the large inversion should be performed.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Approximately 1%-2% of North Americans of northern European background have the deep intronic splicing variant or the large inversion [Qian, personal communication (2012)].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><italic toggle="yes">STXBP2</italic> pathogenic variants account for about 20% of pathogenic variants in North American persons with FHL and have been identified in all ethnic/racial groups tested [Johnson, unpublished data (2012)]. Therefore, sequence analysis for <italic toggle="yes">STXBP2</italic> is appropriate in any person with suspected FHL for whom molecular genetic testing of <italic toggle="yes">PRF1</italic> and <italic toggle="yes">UNC13D</italic> is normal. Of note, no gross deletions, insertions, or complex rearrangements have been identified in <italic toggle="yes">STXBP2</italic> to date.</p>
            </list-item>
            <list-item>
              <p>Pathogenic variants in <italic toggle="yes">STX11</italic> account for about 1% of the pathogenic variants in North American individuals and about 5% of central European individuals with HLH. Sequence analysis or scanning of <italic toggle="yes">STX11</italic> for pathogenic variants should follow <italic toggle="yes">PRF1, UNC13D</italic>, and <italic toggle="yes">STXBP2</italic> variant analyses that do not identify at least one pathogenic variant. If sequence analysis is normal, deletion/duplication analysis of <italic toggle="yes">STX11</italic> can be considered, as gross deletions have been reported in <italic toggle="yes">STX11</italic>. Pathogenic variants in <italic toggle="yes">STX11</italic> have been identified in most racial/ethnic groups [<xref ref-type="bibr" rid="hlh.REF.marsh.2010b.134">Marsh et al 2010b</xref>].</p>
            </list-item>
          </list>
          <p>In symptomatic individuals not found to have pathogenic variants in <italic toggle="yes">PRF1</italic>, <italic toggle="yes">UNC13D</italic>, <italic toggle="yes">STX11</italic>, or <italic toggle="yes">STXBP2</italic>, sequencing of <italic toggle="yes">RAB27A</italic> for Griscelli syndrome type 2 (see <xref ref-type="sec" rid="hlh.Differential_Diagnosis">Differential Diagnosis</xref>) should be considered.</p>
          <p>Note: Approximately 2%-3% of North American individuals with FHL have pathogenic variants in <italic toggle="yes">RAB27A.</italic> These individuals may not show evidence of partial albinism or other pigmentary abnormalities typically reported with Griscelli syndrome type 2 [Johnson, unpublished data (2012)].</p>
          <p>In males with symptoms of HLH not found to have pathogenic variants in <italic toggle="yes">PRF1</italic>, <italic toggle="yes">UNC13D</italic>, <italic toggle="yes">STX11,</italic>
<italic toggle="yes">STXBP2,</italic> or <italic toggle="yes">RAB27A</italic>, molecular genetic testing of <italic toggle="yes">XIAP</italic> (also known as <italic toggle="yes">BIRC4</italic>) and <italic toggle="yes">SH2D1A</italic> should be considered (see <xref ref-type="sec" rid="hlh.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of two pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic sibs of a proband requires prior identification of two pathogenic variants in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of two pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="hlh.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="hlh.Clinical_Description">
          <title>Clinical Description</title>
          <p>Symptoms of familial hemophagocytic lymphohistiocytosis (FHL) are usually evident within the first months or years of life [<xref ref-type="bibr" rid="hlh.REF.aric_.1996.197">Aric&#x000f2; et al 1996</xref>] and may even develop in utero [<xref ref-type="bibr" rid="hlh.REF.malloy.2004.458">Malloy et al 2004</xref>]. However, symptomatic presentation throughout childhood and even into adulthood has been observed in some cases [<xref ref-type="bibr" rid="hlh.REF.aric_.1996.197">Aric&#x000f2; et al 1996</xref>, <xref ref-type="bibr" rid="hlh.REF.allen.2001.499">Allen et al 2001</xref>, <xref ref-type="bibr" rid="hlh.REF.clementi.2002.2266">Clementi et al 2002</xref>, <xref ref-type="bibr" rid="hlh.REF.zhang.2011.5794">Zhang et al 2011</xref>, <xref ref-type="bibr" rid="hlh.REF.sieni.2012b.e44649">Sieni et al 2012b</xref>].</p>
          <p>FHL usually presents in childhood as an acute illness with prolonged fever (&#x0003e;7 days), cytopenias, and hepatosplenomegaly. Rash and lymphadenopathy are less frequently observed. Liver dysfunction (elevated serum aminotransferase and bilirubin), neurologic dysfunction (irritability or lethargy, hypotonia or hypertonia, seizures, ataxia, and cranial nerve involvement presenting as nerve palsy and blindness), and bone marrow hemophagocytosis complete the typical presentation of the disorder.</p>
          <p>Oftentimes, FHL is associated with documented infection, especially herpes viral infections [<xref ref-type="bibr" rid="hlh.REF.imashuku.2005.315">Imashuku et al 2005</xref>] and leishmaniasis [<xref ref-type="bibr" rid="hlh.REF.filipovich.2011.512">Filipovich 2011</xref>].</p>
          <p>In adults, FHL may present with acute onset of full-blown HLH, or as a more insidious illness with recurrent bouts of nonspecific symptoms of HLH which may resolve spontaneously or with steroid treatment alone. HLH in adults is often erroneously attributed to an infectious etiology without a full genetic workup being undertaken.</p>
          <p>
            <bold>Common signs and symptoms</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Fever</bold> is frequently indolent and protracted but may decline spontaneously. In a few children, it may develop late in the course of the disease.</p>
            </list-item>
            <list-item>
              <p><bold>Splenomegaly</bold> and <bold>hepatomegaly</bold> are usually pronounced and progressive.</p>
            </list-item>
            <list-item>
              <p><bold>Skin rash</bold> is uncharacteristic, transient, and often associated with high fever.</p>
            </list-item>
            <list-item>
              <p><bold>Lymph node enlargement</bold> develops in fewer than 50% of individuals but may occasionally be significant.</p>
            </list-item>
            <list-item>
              <p><bold>Neurologic abnormalities</bold> may be present at initial clinical presentation or in many instances may develop later in the course of the disease. The presentation may include irritability, bulging fontanel in infants, neck stiffness, hypotonia, hypertonia, and convulsions. Cranial nerve VI and/or VII palsy, ataxia, hemiplegia, quadriplegia, blindness, and coma may occur, as well as nonspecific signs of increased intracranial pressure. On examination of CSF, elevated protein, increased number of mononuclear cells, and occasionally hemophagocytosis are characteristic findings. MRI may show gross demyelination or failure of normal myelination during the first year of life. MRI may also show multifocal inflammation involving gray and white matter. Bleeding, generalized atrophy, and brain edema may be observed. Hyperdense areas on CT may be falsely interpreted as calcifications.</p>
            </list-item>
            <list-item>
              <p><bold>Life expectancy.</bold> Median survival in typical FHL, without treatment, is less than two months. Progressive hemophagocytic lymphohistiocytosis (HLH) and invasive infection account for the majority of deaths in untreated children [<xref ref-type="bibr" rid="hlh.REF.sung.2002.550">Sung et al 2002</xref>]. Although children can survive without hematopoietic cell transplantation (HCT) [<xref ref-type="bibr" rid="hlh.REF.henter.2002.2367">Henter et al 2002</xref>], the five-year survival of children treated with chemotherapy alone was only 10.1% in one large series. Allogeneic hematopoietic stem cell transplantation is potentially curative (see <xref ref-type="sec" rid="hlh.Management">Management</xref>).</p>
            </list-item>
            <list-item>
              <p>The course of the disease and life expectancy are not well studied in adults with FHL.</p>
            </list-item>
          </list>
        </sec>
        <sec id="hlh.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Both Feldmann and Molleran Lee documented poor correlation between phenotype and genotype in FHL2 with different classes of <italic toggle="yes">PRF1</italic> pathogenic variants [<xref ref-type="bibr" rid="hlh.REF.feldmann.2002.965">Feldmann et al 2002</xref>, <xref ref-type="bibr" rid="hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</xref>].</p>
          <p>In general, age of onset tends to be younger in those with nonsense versus missense <italic toggle="yes">PRF1</italic> variants [<xref ref-type="bibr" rid="hlh.REF.clementi.2002.2266">Clementi et al 2002</xref>, <xref ref-type="bibr" rid="hlh.REF.feldmann.2002.965">Feldmann et al 2002</xref>, <xref ref-type="bibr" rid="hlh.REF.zur_stadt.2006.62">zur Stadt et al 2006</xref>, <xref ref-type="bibr" rid="hlh.REF.trizzino.2008.15">Trizzino et al 2008</xref>]. In particular, homozygosity for the <italic toggle="yes">PRF1</italic>
<xref ref-type="table" rid="hlh.T.selected_prf1_allelic_variants">p.Leu17ArgfsTer34</xref> pathogenic variant, commonly seen in affected individuals of African descent, is associated with an earlier onset (median age 3 months; range 1.5-10 months) compared to other <italic toggle="yes">PRF1</italic> pathogenic missense variants [<xref ref-type="bibr" rid="hlh.REF.lee.2006.134">Lee et al 2006</xref>]. However, affected individuals within the same family may develop evidence of disease at different ages [<xref ref-type="bibr" rid="hlh.REF.allen.2001.499">Allen et al 2001</xref>].</p>
          <p>In a study of 35 Japanese individuals with FHL, <xref ref-type="bibr" rid="hlh.REF.ishii.2005.3442">Ishii et al [2005]</xref> concluded that persons with pathogenic variants of <italic toggle="yes">PRF1</italic> had earlier disease onset than those with pathogenic variants of <italic toggle="yes">UNC13D</italic> or FHL for whom no genetic basis was established.</p>
          <p>Deficient NK cell activity persisted after chemotherapy in all persons with FHL2, whereas some individuals with FHL3 or the non-FHL2/FHL3 subtype showed partial recovery of NK cell activity during remission.</p>
          <p>Alloantigen-specific CTL-mediated cytotoxicity was deficient in individuals with FHL2 with <italic toggle="yes">PRF1</italic> pathogenic nonsense variants and very low in individuals with FHL3, but was only moderately reduced in individuals with FHL2 with <italic toggle="yes">PRF1</italic> pathogenic missense variants [<xref ref-type="bibr" rid="hlh.REF.ishii.2005.3442">Ishii et al 2005</xref>].</p>
          <p><xref ref-type="bibr" rid="hlh.REF.ueda.2006.179">Ueda et al [2006]</xref> found that the incidence of deficient NK cell activity was higher in those with <italic toggle="yes">PRF1</italic> pathogenic variants than in those with <italic toggle="yes">UNC13D</italic> or uncharacterized pathogenic variants. In addition, pathogenic nonsense variants in <italic toggle="yes">PRF1</italic> were associated with significantly higher levels of ferritin and soluble Il2Ra than observed in other subtypes of FHL.</p>
          <p><xref ref-type="bibr" rid="hlh.REF.horne.2008.75">Horne et al [2008]</xref> concluded that persons with pathogenic variants of <italic toggle="yes">PRF1</italic> had earlier onset of symptoms than those with pathogenic variants of <italic toggle="yes">STX11</italic>, and that the latter had a somewhat milder disease course than those with <italic toggle="yes">PRF1</italic> variants, <italic toggle="yes">UNC13D</italic> variants<italic toggle="yes">,</italic> or uncharacterized pathogenic variants. <xref ref-type="bibr" rid="hlh.REF.rudd.2006.e14">Rudd et al [2006]</xref> reported long remissions without specific treatments in some individuals with <italic toggle="yes">STX11</italic> pathogenic variants. They also reported a higher than expected incidence of psychomotor retardation and myelodysplastic syndrome or acute myelogenous leukemia in their small group with <italic toggle="yes">STX11</italic> pathogenic variants. <xref ref-type="bibr" rid="hlh.REF.marsh.2010b.134">Marsh et al [2010b]</xref> noted that pathogenic missense variants in <italic toggle="yes">STX11</italic> were associated with later onset and preserved NK cell function compared to nonsense variants in <italic toggle="yes">STX11</italic>, which resulted in abrogation of NK cell function.</p>
          <p>In general, the age of onset of disease tends to be later in individuals with pathogenic variants of <italic toggle="yes">STXBP2</italic> [<xref ref-type="bibr" rid="hlh.REF.meeths.2010b.2635">Meeths et al 2010b</xref>] than it is in individuals with pathogenic variants of <italic toggle="yes">PRF1</italic> or <italic toggle="yes">UNC13D;</italic> however, age of onset is variable, even within the same family. Later age at onset in persons with the common <xref ref-type="table" rid="hlh.T.selected_stxbp2_allelic_variants">c.1247-1G&#x0003e;C</xref> variant in <italic toggle="yes">STXBP2</italic> (both in the homozygous and compound heterozygous states) in comparison to individuals with various missense variants has been reported [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</xref>, <xref ref-type="bibr" rid="hlh.REF.pagel.2012.6016">Pagel et al 2012</xref>]. In contrast, the authors have observed onset of HLH in infancy in more than half of individuals with the c.1247-1G&#x0003e;C variant, as well as considerable discordance in phenotype and age at onset between sibs with the same genotype [Johnson, unpublished data (2012)]. Gastrointestinal disorders, bleeding diathesis, and hypogammaglobulinemia, with onset often prior to symptoms of HLH, has been reported in a subset of individuals with pathogenic variants of <italic toggle="yes">STBXP2</italic> [<xref ref-type="bibr" rid="hlh.REF.meeths.2010b.2635">Meeths et al 2010b</xref>].</p>
          <p>Adult onset of disease in individuals with FHL-causing pathogenic variant(s) has been well described [<xref ref-type="bibr" rid="hlh.REF.allen.2001.499">Allen et al 2001</xref>, <xref ref-type="bibr" rid="hlh.REF.clementi.2002.2266">Clementi et al 2002</xref>, <xref ref-type="bibr" rid="hlh.REF.ueda.2006.179">Ueda et al 2006</xref>]. Missense and splice site variants in <italic toggle="yes">PRF1</italic>, <italic toggle="yes">UNC13D</italic> and <italic toggle="yes">STXBP2</italic> were recently reported in 14% of adults with HLH [<xref ref-type="bibr" rid="hlh.REF.zhang.2011.5794">Zhang et al 2011</xref>]. Similarly, <xref ref-type="bibr" rid="hlh.REF.sieni.2012b.e44649">Sieni et al [2012b]</xref> identified 11 adults with FHL secondary to pathogenic variants in <italic toggle="yes">PRF1</italic>, <italic toggle="yes">UNC13D</italic>, <italic toggle="yes">STXBP2</italic>, and <italic toggle="yes">SH2D1A</italic>. In both studies, the <xref ref-type="table" rid="hlh.T.selected_prf1_allelic_variants">p.Ala91Var</xref> variant in <italic toggle="yes">PRF1</italic> was the most commonly identified variant. While p.Ala91Var is not by itself pathogenic, it does have an effect on cytotoxic function [<xref ref-type="bibr" rid="hlh.REF.voskoboinik.2005.4700">Voskoboinik et al 2005</xref>] and may function as a genetic modifier of disease in some affected individuals.</p>
        </sec>
        <sec id="hlh.Nomenclature">
          <title>Nomenclature</title>
          <p><bold>Classification.</bold> The widely used modern classification of histiocytic disorders was proposed by the Histiocyte Society in 1987 and refined in 1998.</p>
          <p>The Writing Group of the Histiocyte Society recommended a division of the histiocytic disorders into three classes:</p>
          <list list-type="bullet">
            <list-item>
              <p>Dendritic cell-related disorders, of which Langerhan's cell histiocytosis (LCH) is by far the most common</p>
            </list-item>
            <list-item>
              <p>Macrophage-related disorders (including hemophagocytic lymphohistiocytosis [HLH])</p>
            </list-item>
            <list-item>
              <p>Malignant disorders</p>
            </list-item>
          </list>
          <p>
            <bold>Naming</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>FHL was once called familial erythrophagocytic lymphohistiocytosis (FEL).</p>
            </list-item>
            <list-item>
              <p>FHL occurring in conjunction with identified viral infections was termed VAHS (virus-associated hemophagocytic syndrome); however, it is now recognized that FHL may be triggered by viral infection.</p>
            </list-item>
            <list-item>
              <p>The general term hemophagocytic lymphohistiocytosis (HLH) encompasses all forms of the disorder.</p>
            </list-item>
          </list>
        </sec>
        <sec id="hlh.Prevalence">
          <title>Prevalence</title>
          <p>The estimated prevalence of FHL is 1:50,000 births [<xref ref-type="bibr" rid="hlh.REF.henter.1998.417">Henter et al 1998</xref>] with equal gender distribution.</p>
          <p>A common <italic toggle="yes">PRF1</italic> pathogenic variant, <xref ref-type="table" rid="hlh.T.selected_prf1_allelic_variants">p.Leu17ArgfsTer34</xref>, has been observed at a high frequency in individuals with FHL in the African American population [<xref ref-type="bibr" rid="hlh.REF.lee.2006.134">Lee et al 2006</xref>].</p>
        </sec>
      </sec>
      <sec id="hlh.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">PRF1</italic>.</bold> There are reports of other phenotypes associated with mutation of <italic toggle="yes">PRF1</italic>; the pathologic consequences are not well defined.</p>
        <list list-type="bullet">
          <list-item>
            <p><xref ref-type="bibr" rid="hlh.REF.clementi.2005.4424">Clementi et al [2005]</xref> reported <italic toggle="yes">PRF1</italic> sequence variants in a proportion of persons with lymphoma:</p>
            <list list-type="bullet">
              <list-item>
                <p>Two of four individuals with lymphoma had two <italic toggle="yes">PRF1</italic> sequence variants, one of which is <xref ref-type="table" rid="hlh.T.selected_prf1_allelic_variants">c.272C&#x0003e;T</xref> (<xref ref-type="table" rid="hlh.T.selected_prf1_allelic_variants">p.Ala91Val</xref>), found in about 3% of controls [<xref ref-type="bibr" rid="hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</xref>] and for which understanding of the pathogenic effect is still controversial (see <xref ref-type="sec" rid="hlh.Molecular_Genetics">Molecular Genetics</xref>).</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="hlh.REF.solomou.2007.5234">Solomou et al [2007]</xref> reported an association between mutation of <italic toggle="yes">PRF1</italic> and acquired aplastic anemia. Three of five reported individuals had the c.272C&#x0003e;T variant described above; a fourth had the <xref ref-type="table" rid="hlh.T.selected_prf1_allelic_variants">c.11G&#x0003e;A</xref> (<xref ref-type="table" rid="hlh.T.selected_prf1_allelic_variants">p.Arg4His</xref>) variant, a common benign variant in African Americans [<xref ref-type="bibr" rid="hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</xref>]; the fifth had a novel sequence variant. All affected individuals were reported to have absent or markedly reduced perforin expression and absent perforin staining on microscopy; four of the five had hemophagocytosis in bone marrow.</p>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="hlh.REF.chia.2009.9809">Chia et al [2009]</xref> examined temperature-sensitive <italic toggle="yes">PRF1</italic> missense variants in a subset of individuals with biallelic <italic toggle="yes">PRF1</italic> pathogenic variants who had not developed hemophagocytic lymphohistiocytosis (HLH) by age ten years. 50% developed at least one hematologic malignancy by adulthood.</p>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="hlh.REF.orilieri.2008.1078">Orilieri et al [2008]</xref> reported an association between the p.Asn252Ser (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001083116.1">NM_001083116.1</ext-link>:c.755A&#x0003e;G) variant in <italic toggle="yes">PRF1</italic> and type 1 diabetes mellitus.</p>
          </list-item>
          <list-item>
            <p><xref ref-type="bibr" rid="hlh.REF.cannella.2007.2566">Cannella et al [2007]</xref> described 44 persons with childhood anaplastic large-cell lymphoma, 27.3% of whom had sequence variants in <italic toggle="yes">PRF1</italic> compared to 10.2% in the general population (p&#x0003c;.01).</p>
          </list-item>
        </list>
        <p><bold><italic toggle="yes">UNC13D.</italic></bold>
<xref ref-type="bibr" rid="hlh.REF.zhang.2008.2892">Zhang et al [2008]</xref> reported an association between mutation of <italic toggle="yes">UNC13D</italic> and a specific haplotype with sJIA with macrophage activation syndrome (MAS). However, <xref ref-type="bibr" rid="hlh.REF.donn.2008.869">Donn et al [2008]</xref> failed to confirm an association between systemic onset sJIA/MAS and sequence variants or specific haplotypes in <italic toggle="yes">PRF1</italic>, <italic toggle="yes">GZMB</italic>, <italic toggle="yes">UNC13D</italic>, or <italic toggle="yes">RAB27A</italic>.</p>
        <p><bold><italic toggle="yes">STX11</italic>.</bold> No other phenotypes are known to be associated with mutation of <italic toggle="yes">STX11</italic>.</p>
        <p><bold><italic toggle="yes">STXBP2.</italic></bold> A secondary phenotype consisting of colitis, bleeding disorders, and hypogammaglobulinemia has been described in approximately one third of individuals with pathogenic variants in <italic toggle="yes">STXBP2</italic> [<xref ref-type="bibr" rid="hlh.REF.meeths.2010b.2635">Meeths et al 2010b</xref>]. This phenotype may precede the development of symptoms of HLH; however, data are insufficient to determine if all individuals with pathogenic variants in <italic toggle="yes">STXBP2</italic> who have this secondary phenotype will develop symptoms of HLH.</p>
      </sec>
      <sec id="hlh.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Secondary (acquired or reactive) hemophagocytic lymphohistiocytosis (HLH)</bold> is difficult to distinguish from familial (primary) HLH by clinical or histologic findings alone. Given the rapid advances in genetic diagnosis of FHL, molecular genetic testing is recommended even in HLH suspected to be acquired.</p>
        <p>The diagnosis of secondary HLH is usually made in association with infection by viruses, bacteria, fungi, or parasites or in association with lymphoma, autoimmune disease, or metabolic disease [<xref ref-type="bibr" rid="hlh.REF.imashuku.2000.37">Imashuku et al 2000</xref>, <xref ref-type="bibr" rid="hlh.REF.imashuku.2005.315">Imashuku et al 2005</xref>]. Acquired HLH may have decreased, normal, or increased NK cell activity.</p>
        <p>Secondary HLH appears to be self-limited because some affected individuals are able to fully recover having received supportive medical treatment (i.e., IV immunoglobulin) alone. However, long-term remission without the use of cytotoxic and immune-suppressive therapies is highly unlikely in adults with HLH and in individuals with CNS involvement [<xref ref-type="bibr" rid="hlh.REF.imashuku.1999.1869">Imashuku et al 1999</xref>].</p>
        <p>Secondary HLH is usually associated with:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Infection,</bold> particularly involving the herpes virus group, usually in older children and adolescents [<xref ref-type="bibr" rid="hlh.REF.fisman.2000.601">Fisman 2000</xref>]. An example is EBV (Epstein-Barr virus)-associated HLH, which is more common in Asians than in whites or Africans [<xref ref-type="bibr" rid="hlh.REF.ma.2001.358">Ma et al 2001</xref>]. Also in one case, compound heterozygosity for two pathogenic missense variants in <italic toggle="yes">PRF1</italic> was associated with chronic active EBV infection with hemophagocytic lymphohistiocytosis [<xref ref-type="bibr" rid="hlh.REF.katano.2004.1244">Katano et al 2004</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>&#x02018;Macrophage activation syndrome&#x02019; (MAS),</bold> the most serious and life-threatening complication of systemic-onset juvenile idiopathic arthritis (sJIA). MAS was first described by <xref ref-type="bibr" rid="hlh.REF.hadchouel.1985.561">Hadchouel et al [1985]</xref> as a hemorrhagic syndrome associated with mental status changes, hepatosplenomegaly, increased serum concentrations of liver enzymes, and a sharp fall in blood counts. The term MAS was coined by <xref ref-type="bibr" rid="hlh.REF.st_phan.1993.451">St&#x000e9;phan et al [1993]</xref> in reference to the bone marrow histologic findings of numerous, well-differentiated macrophages (or histiocytes) actively phagocytosing hematopoietic elements. Such cells may infiltrate many organs in MAS. MAS responds to therapies similar to those typically effective in HLH. The amount of perforin expressed in NK cells from individuals with severe sJRA is less than in normal controls [<xref ref-type="bibr" rid="hlh.REF.normand.2000.5406">Normand et al 2000</xref>], suggesting a mechanism of immune susceptibility to hemophagocytic lymphohistiocytosis (HLH) similar to FHL2. More recent studies also show that natural killer cell dysfunction is a distinguishing feature of sJIA and MAS [<xref ref-type="bibr" rid="hlh.REF.villanueva.2005.r30">Villanueva et al 2005</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Autoimmune diseases,</bold> such as rheumatologic disorders, treated with immune suppressive agents [<xref ref-type="bibr" rid="hlh.REF.janka.1998.435">Janka et al 1998</xref>]. Secondary HLH is most commonly associated with sJIA, but has also been observed in systemic lupus erythematosus [<xref ref-type="bibr" rid="hlh.REF.muiesan.1998.794">Muiesan et al 1998</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Inborn errors of metabolism</bold> including <related-object link-type="booklink" source-id="gene" document-id="biotin" document-type="chapter">biotinidase deficiency</related-object> [<xref ref-type="bibr" rid="hlh.REF.kardas.2012.191">Kardas et al 2012</xref>], <related-object link-type="booklink" source-id="gene" document-id="lpi" document-type="chapter">lysinuric protein intolerance</related-object> [<xref ref-type="bibr" rid="hlh.REF.duval.1999.236">Duval et al 1999</xref>], <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">galactosemia</related-object> [<xref ref-type="bibr" rid="hlh.REF.marcoux.2005.160">Marcoux et al 2005</xref>], multiple sulfatase deficiency, <related-object link-type="booklink" source-id="gene" document-id="gaucher" document-type="chapter">Gaucher disease</related-object>, <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Pearson syndrome</related-object>, galactosialidosis, <related-object link-type="booklink" source-id="gene" document-id="mma" document-type="chapter">methylmalonic acidemia</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="propionic-a" document-type="chapter">propionic acidemia</related-object> [<xref ref-type="bibr" rid="hlh.REF.gokce.2012.92">Gokce et al 2012</xref>] have all been reported in association with secondary hemophagocytic lymphohistiocytosis in some individuals. It is not known how these metabolic disorders lead to HLH.</p>
          </list-item>
        </list>
        <p><bold>Inherited immune disorders</bold> can be associated with highly lethal hemophagocytic syndromes, sometimes triggered by exposure to EBV or other viruses. These include the following:</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="x-lpd" document-type="chapter"><bold>X-linked lymphoproliferative disease</bold></related-object>
<bold>(XLP)</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>XLP1, caused by SAP deficiency, results from hemizygous mutation of <italic toggle="yes">SH2D1A</italic>. The three main phenotypes of this type of XLP are an inappropriate immune response to Epstein-Barr virus (EBV) infection resulting in unusually <bold>severe and often fatal infectious mononucleosis, dysgammaglobulinemia,</bold> and/or <bold>lymphoproliferative disorders</bold> typically of B cell origin. Clinical manifestations of XLP1 vary, even among affected family members. The most common presentation is a near-fatal or fatal EBV infection associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages. Mortality is greater than 90%. In about one third of males with XLP1, hypogammaglobulinemia of one or more immunoglobulin subclasses is diagnosed prior to EBV infection or in rare survivors of EBV infection. The prognosis for males with this phenotype is more favorable if they are managed with regular IV IgG. Lymphomas or other lymphoproliferative disease occur in about one third of males with XLP1, some of whom have hypogammaglobulinemia or have survived an initial EBV infection. The lymphomas seen in XLP1 are typically high-grade B cell lymphomas, non-Hodgkin type, often extranodal, and particularly involving the intestine. Allogeneic HSCT is the only curative therapy for XLP1 and should be undertaken in confirmed cases of XLP1 as early in life as feasible. Average life expectancy without curative bone marrow transplantation has been estimated as less than ten years. Inheritance is X-linked recessive.</p>
          </list-item>
          <list-item>
            <p>XLP2, caused by XIAP deficiency and resulting from mutation of <italic toggle="yes">XIAP</italic> (aka <italic toggle="yes">BIRC4</italic>), is located (as the name implies) on the X chromosome [<xref ref-type="bibr" rid="hlh.REF.rigaud.2006.110">Rigaud et al 2006</xref>]. The most common manifestation of XIAP deficiency is the development of HLH, which is often recurrent. Because of this, it has recently been suggested that XIAP deficiency may be best classified as a cause of X-linked HLH [<xref ref-type="bibr" rid="hlh.REF.marsh.2010a.1079">Marsh et al 2010a</xref>].</p>
            <list list-type="bullet">
              <list-item>
                <p>Hypogammaglobulinemia and colitis have also been described in individuals with XIAP deficiency. In contrast to XLP1, no cases of lymphoma have been observed in individuals with XIAP deficiency [<xref ref-type="bibr" rid="hlh.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al 2011</xref>]. Patient management includes treatment of HLH when it occurs, immunoglobulin replacement if needed, and consideration of allogeneic bone marrow transplant.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p><related-object link-type="booklink" source-id="gene" document-id="chediak-higashi" document-type="chapter"><bold>Chediak-Higashi syndrome</bold></related-object> is a complex syndrome characterized by partial albinism, abnormal platelet function, and severe immunodeficiency. This disorder is caused by mutation of <italic toggle="yes">CHS1</italic>, which encodes a protein involved in intracellular vesicle formation, resulting in a failure to fuse lysosomes properly with phagosomes. Chediak-Higashi syndrome can be differentiated from FHL based on the presence of huge secretory lysosomes in the neutrophils and lymphocytes and giant melanosomes on skin biopsy. Inheritance is autosomal recessive.</p>
        <p><bold>Griscelli syndrome type 2 (GS2)</bold> is a disorder of cytotoxic T lymphocytes caused by mutation of a small GTPase, <italic toggle="yes">RAB27A</italic>, which controls the movement of vesicles within cells [<xref ref-type="bibr" rid="hlh.REF.m_nasch_.2000.173">M&#x000e9;nasch&#x000e9; et al 2000</xref>]. GS2 is usually associated with neurologic abnormalities in addition to partial albinism with fair skin and silvery-grey hair and has an extremely high incidence of HLH. A recent Swedish study identified <italic toggle="yes">RAB27A</italic> pathogenic variants in 5% of individuals with primary HLH and without a known diagnosis of GS2 [<xref ref-type="bibr" rid="hlh.REF.meeths.2010a.563">Meeths et al 2010a</xref>]. GS2 and FHL3 may share a common pathway: <xref ref-type="bibr" rid="hlh.REF.neeft.2005.731">Neeft et al [2005]</xref> showed that the protein encoded by <italic toggle="yes">UNC13D</italic> is a direct partner of the protein RAB27A, and that the RAB27A/UNC13D complex is essential in the regulation of secretory granule fusion with the plasma membrane in hematopoietic cells. Inheritance is autosomal recessive.</p>
      </sec>
      <sec id="hlh.Management">
        <title>Management</title>
        <sec id="hlh.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with hemophagocytic lymphohistiocytosis (HLH), as well as to determine the appropriate therapy, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Physical examination to evaluate for rashes, lymphadenopathy, hepatosplenomegaly, and neurologic dysfunction</p>
            </list-item>
            <list-item>
              <p>Evaluation of blood and bone marrow compartments (CBC and BM biopsy)</p>
            </list-item>
            <list-item>
              <p>Determination of the extent of liver involvement by measuring serum concentration of transaminases, bilirubin, triglycerides, sodium, and lactate dehydrogenase</p>
            </list-item>
            <list-item>
              <p>Identification of potential infectious co-factors, especially viral infection or reactivation, which would require specific treatment</p>
            </list-item>
            <list-item>
              <p>Establishing the presence or extent of CNS involvement by evaluating the CSF and performing neuroimaging and neuropsychological assessment</p>
            </list-item>
            <list-item>
              <p>Testing of NK cell activity, intracellular perforin and granzyme B expression, and CD107a mobilization if these tests are available</p>
            </list-item>
            <list-item>
              <p>Evaluation of inflammatory factors such as serum concentrations of ferritin, sIL2R&#x003b1;, and other cytokines</p>
            </list-item>
            <list-item>
              <p>Evaluation and monitoring of PT, PTT, and fibrinogen</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing, if not performed previously, which may help to determine if an affected individual is a candidate for bone marrow transplantation:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Genetic testing for <italic toggle="yes">PRF1</italic>, <italic toggle="yes">UNC13D</italic>, <italic toggle="yes">STX11</italic>, and <italic toggle="yes">STXBP2</italic> pathogenic variants</p>
                </list-item>
                <list-item>
                  <p>Consideration of testing for <italic toggle="yes">RAB27A</italic> pathogenic variants in any individual with HLH, even with no obvious evidence of depigmentation</p>
                </list-item>
                <list-item>
                  <p>Consideration of testing for <italic toggle="yes">XIAP</italic> (formerly <italic toggle="yes">BIRC4</italic>) and <italic toggle="yes">SH2D1A</italic> pathogenic variants in any male with HLH</p>
                </list-item>
                <list-item>
                  <p>Collection of materials for future characterization of underlying genetic defects, most significantly in individuals with terminal disease</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="hlh.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>For a detailed explanation of treatment for HLH, see <xref ref-type="bibr" rid="hlh.REF.jordan.2011.4041">Jordan et al [2011]</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204727/">full text</ext-link>).</p>
          <p><bold>HLH-1994.</bold> To improve survival, in 1994 the Histiocyte Society initiated a prospective international collaborative therapeutic study. It combined chemotherapy and immunotherapy (etoposide, corticosteroids, cyclosporine A, and intrathecal methotrexate for individuals with CNS diseases), followed by HSCT in persistent, recurring, and/or familial disease. Although HLH-94 was primarily designed for the treatment of FHL, it was also open to all individuals with non-familial HLH.</p>
          <p><bold>HLH-2004.</bold> The HLH-2004 protocol was opened on January 1, 2004, and was designed for individuals with FHL and non-familial HLH. This protocol was based on the HLH-94 protocol with minor therapeutic modifications such as initiation of cyclosporine from onset of induction therapy.</p>
          <p>The two protocols developed by the Histiocyte Society are available from the Histiocyte Society <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.histiocytesociety.org/">website</ext-link>.</p>
          <p>Given the poor prognosis of individuals with HLH without prompt and effective treatment, it is recommended that treatment be initiated when clinical suspicion is high, even if all recommended studies are incomplete. In general, treatment involves the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Chemotherapy and immunotherapy to achieve a clinically stable resolution prior to hematopoietic cell transplantation (HCT)</p>
            </list-item>
            <list-item>
              <p>Antibiotics or antiviral agents to treat or prevent infections that may have triggered the exaggerated inflammatory response</p>
            </list-item>
            <list-item>
              <p>Allogeneic HCT, the only curative therapy, which should be undertaken in children with confirmed FHL as early in life as feasible:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Presymptomatically if status is confirmed by family history of clinical HLH, or</p>
                </list-item>
                <list-item>
                  <p>After achievement of clinical remission in simplex cases (i.e., a single occurrence in a family)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Use of HCT has improved survival significantly [<xref ref-type="bibr" rid="hlh.REF.henter.2002.2367">Henter et al 2002</xref>]. Initially, three-year-survival in children who received HLH-94 therapy was approximately 64% [<xref ref-type="bibr" rid="hlh.REF.horne.2005a.622">Horne et al 2005a</xref>]. More recently, reduced intensity regimens prior to HCT have diminished the early transplant mortality and increased three-year-survival rates to 92% [<xref ref-type="bibr" rid="hlh.REF.marsh.2010c.5824">Marsh et al 2010c</xref>]. Long-term follow up reveals that after HCT most children treated early in the disease course return to normal or near-normal quality of life. Brain atrophy secondary to steroid therapy often identified on neuroimaging studies during the acute phase of HLH gradually resolves after HCT [<xref ref-type="bibr" rid="hlh.REF.shuper.1998.126">Shuper et al 1998</xref>]. However, children who experienced serious CNS involvement may have irreversible neurologic problems and learning disabilities despite adequate disease control following HCT.</p>
            </list-item>
          </list>
        </sec>
        <sec id="hlh.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>Allogeneic HCT is the only curative therapy and should be undertaken in children with confirmed familial HLH as early in life as possible.</p>
        </sec>
        <sec id="hlh.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Prompt treatment of HLH with infection prophylaxis is indicated in immunocompromised individuals.</p>
        </sec>
        <sec id="hlh.Surveillance">
          <title>Surveillance</title>
          <p>The following are recommended annually after HCT:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neuropsychological evaluation</p>
            </list-item>
            <list-item>
              <p>Regular follow-up by transplant specialists to monitor for late complications relating to growth and hormone function</p>
            </list-item>
          </list>
        </sec>
        <sec id="hlh.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The following should be avoided:</p>
          <list list-type="bullet">
            <list-item>
              <p>Live vaccinations</p>
            </list-item>
            <list-item>
              <p>Exposure to infections</p>
            </list-item>
          </list>
        </sec>
        <sec id="hlh.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Molecular genetic testing of at-risk sibs for the family-specific pathogenic variants is appropriate to identify those who are affected before symptoms occur for the purpose of early medical management and consideration of presymptomatic bone marrow transplantation.</p>
          <p>See <xref ref-type="sec" rid="hlh.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="hlh.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>To date, pregnancy in a woman with primary FHL has not been described. Secondary hemophagocytic lymphohistiocytosis is a rare complication of pregnancy and is beyond the scope of this review. Primary hemophagocytic lymphohistiocytosis in the fetus is a (reportedly) rare but recognized entity which is typically characterized by nonimmune fetal hydrops [<xref ref-type="bibr" rid="hlh.REF.malloy.2004.458">Malloy et al 2004</xref>, <xref ref-type="bibr" rid="hlh.REF.nitta.2007.98">Nitta et al 2007</xref>, <xref ref-type="bibr" rid="hlh.REF.woods.2009.265">Woods et al 2009</xref>], preterm delivery [<xref ref-type="bibr" rid="hlh.REF.woods.2009.265">Woods et al 2009</xref>], and/or fetal demise. In utero chemotherapy followed by post-natal HCT has been described [<xref ref-type="bibr" rid="hlh.REF.shah.2009.139">Shah et al 2009</xref>].</p>
        </sec>
        <sec id="hlh.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="hlh.Other">
          <title>Other</title>
          <p>The treatment of FHL is also the most effective treatment for secondary HLH and the hemophagocytic syndrome associated with other inherited immunodeficiencies.</p>
        </sec>
      </sec>
      <sec id="hlh.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="hlh.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Familial hemophagocytic lymphohistiocytosis (FHL) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="hlh.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one mutated allele.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with FHL are obligate heterozygotes (carriers).</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="hlh.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing is possible if the pathogenic variants in the family are known.</p>
        </sec>
        <sec id="hlh.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="hlh.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Testing of at-risk asymptomatic sibs</bold> for FHL is possible using the techniques described in <xref ref-type="sec" rid="hlh.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>. Such testing is not useful in accurately predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. However, expectant management is warranted for individuals with the same genotype as the symptomatic proband and HCT prior to onset of symptoms may improve outcome.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="hlh.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the pathogenic variants have been identified in an affected family member, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis are possible options.</p>
        </sec>
      </sec>
      <sec id="hlh.Resources">
        <title>Resources</title>
      </sec>
      <sec id="hlh.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p>
          <bold>
            <italic toggle="yes">PRF1</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">PRF1</italic> has three exons; exons 2 and 3 encode a 555-amino acid polypeptide. Genomic DNA of <italic toggle="yes">PRF1</italic> spans about 5 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hlh" object-id="hlh.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> To date, several benign variants have been observed (see <xref ref-type="table" rid="hlh.T.selected_prf1_allelic_variants">Table 3</xref>). These have been evaluated by biochemical and functional testing in vitro and are highly unlikely to have pathogenic effects on perforin expression.</p>
        <p><bold>Pathogenic allelic variants.</bold> To date, more than 115 pathogenic variants have been identified. They have been found throughout the entire coding region. Pathogenic variants in <italic toggle="yes">PRF1</italic> include nonsense and missense variants, small deletions, and small insertions [<xref ref-type="bibr" rid="hlh.REF.voskoboinik.2005.4700">Voskoboinik et al 2005</xref>]. To date, no gross deletions, splice site variants, or complex rearrangements have been reported.</p>
        <p>The variant c.272C&#x0003e;T has been reported as a pathogenic variant [<xref ref-type="bibr" rid="hlh.REF.clementi.2001.643">Clementi et al 2001</xref>]. This sequence variant is identified in about 3% of the North American general population [<xref ref-type="bibr" rid="hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</xref>] and in a much higher proportion of patients with FHL [<xref ref-type="bibr" rid="hlh.REF.busiello.2006.123">Busiello et al 2006</xref>, <xref ref-type="bibr" rid="hlh.REF.zhang.2007.231">Zhang et al 2007</xref>]. Earlier studies have shown that the sequence change c.272C&#x0003e;T results in reduced levels of perforin expression [<xref ref-type="bibr" rid="hlh.REF.voskoboinik.2005.4700">Voskoboinik et al 2005</xref>] and that p.Ala91Val perforin has reduced cytotoxicity in CTL and NK cells [<xref ref-type="bibr" rid="hlh.REF.trambas.2005.932">Trambas et al 2005</xref>]. In addition, Voskoboinik showed that the c.272C&#x0003e;T (p.Ala91Val) substitution in perforin not only causes reduced steady state levels of expression in effector cells, but also results in a reduced intrinsic capacity for lysis and even had some dominant-negative effect on the wild type perforin [<xref ref-type="bibr" rid="hlh.REF.voskoboinik.2007.1184">Voskoboinik et al 2007</xref>]. Even though c.272C&#x0003e;T by itself is not disease causing, these cumulative data suggest that the sequence variant may be an important genetic susceptibility factor and may play a role in the disease process.</p>
        <table-wrap id="hlh.T.selected_prf1_allelic_variants" position="anchor" orientation="portrait">
          <label>Table 3. </label>
          <caption>
            <p>Selected <italic toggle="yes">PRF1</italic> Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change&#x000a0;<sup>1</sup><break/>(Alias&#x000a0;<sup>2</sup>)</th>
                <th id="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.11G&#x0003e;A</td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg4His</td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_4" rowspan="7" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/133908620">NM_001083116.1</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/133908621">NP_001076585.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.368G&#x0003e;A</td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg123His</td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.726C&#x0003e;T</td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.(=)<break/>(Cys242Cys)</td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.822C&#x0003e;T</td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.(=)<break/>(Ala274Ala)</td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.900C&#x0003e;T</td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.(=)<break/>(His300His)</td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.272C&#x0003e;T&#x000a0;<sup>3</sup></td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala91Val&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.50delT</td>
                <td headers="hd_h_hlh.T.selected_prf1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu17ArgfsTer34</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="hlh.TF.3.1">
              <label>1. </label>
              <p>p.(=) designates that protein has not been analyzed, but no change is expected</p>
            </fn>
            <fn id="hlh.TF.3.2">
              <label>2. </label>
              <p>Variant designation that does not conform to current nomenclature</p>
            </fn>
            <fn id="hlh.TF.3.3">
              <label>3. </label>
              <p>Not disease-causing, but proposed as a genetic susceptibility factor or disease modifier (see <xref ref-type="sec" rid="hlh.Molecular_Genetics"><italic toggle="yes">PRF1</italic></xref><bold><italic toggle="yes">,</italic> Pathogenic allelic variants</bold>)</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">PRF1</italic> encodes the cytolytic effector perforin, which is expressed by cytolytic T lymphocytes and NK cells [<xref ref-type="bibr" rid="hlh.REF.stepp.1999.1957">Stepp et al 1999</xref>]. Perforin expression is higher in resting than in activated cells. Perforin induces apoptotic cell death in response to granzymes (serine esterases that represent most of the granule content of T cytotoxic cells) independent from the FAS-mediated apoptotic machinery.</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">PRF1</italic> pathogenic variants affect cellular cytotoxicity, resulting in impaired antiviral defense and dysregulation of apoptotic mechanisms involved in the regulation of immune responses to inappropriate proliferation of cells, such as T cells and macrophages. Although the mechanisms of regulating perforin expression are incompletely understood, it is known that methylation of a promoter-specific region does affect the level of perforin expression.</p>
        <p>
          <bold><italic toggle="yes">UNC13D</italic> (<italic toggle="yes">MUNC13-4</italic>)</bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">UNC13D</italic> consists of 32 exons ranging from 36 to 235 bp in size. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hlh" object-id="hlh.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> A dozen benign variants, which are highly unlikely to have pathogenic effects on UNC13D protein expression, have been observed.</p>
        <p><bold>Pathogenic allelic variants.</bold> To date, more than 100 pathogenic variants have been identified throughout the entire coding region and the exon/intron boundaries of <italic toggle="yes">UNC13D</italic>. Pathogenic variants that have been identified include missense, nonsense, and splice site variants and small deletions and/or insertions. One deep intronic variant (c.118-308C&#x0003e;T) and one large gene inversion have been detected [<xref ref-type="bibr" rid="hlh.REF.meeths.2011.5783">Meeths et al 2011</xref>]. A large 253-kb inversion straddles the <italic toggle="yes">UNC13D</italic> 3&#x02019; end and adjacent sequences; the breakpoints have been mapped and it is detectable by targeted analysis for pathogenic variants (<xref ref-type="table" rid="hlh.T.summary_of_molecular_genetic_testi">Table 2</xref>). The deep intronic variant lies in a region typically not sequenced; detection will require specific primers.</p>
        <p><bold>Normal gene product.</bold> The protein encoded by <italic toggle="yes">UNC13D</italic> has 1090 amino acids and is a member of the Munc13 protein family, which is an essential effector of the cytolytic secretory pathway. UNC13D differs from the other Munc13 proteins, as it is not expressed in the brain but rather is highly expressed in hematopoietic tissues including T- and B-lymphocytes and monocytes and in non-hematopoietic tissues, such as the lung and the placenta.</p>
        <p>UNC13D is involved in vesicle-plasma membrane fusion during exocytosis of perforin- and granzyme-containing granules by cytotoxic T cells and NK cells [<xref ref-type="bibr" rid="hlh.REF.feldmann.2002.965">Feldmann et al 2002</xref>, <xref ref-type="bibr" rid="hlh.REF.m_nager.2007.257">M&#x000e9;nager et al 2007</xref>], which follows granule docking and precedes plasma granule membrane fusion [<xref ref-type="bibr" rid="hlh.REF.m_nasch_.2005.165">M&#x000e9;nasch&#x000e9; et al 2005</xref>].</p>
        <p>UNC13D is a direct partner of RAB27A. The two proteins are highly expressed in cytotoxic T-cells (CTLs) and mast cells, where they colocalize on secretory lysosomes. Together, they assist priming the vesicles for exocytosis [<xref ref-type="bibr" rid="hlh.REF.m_nager.2007.473">M&#x000e9;nager &#x00026; de Saint Basile 2007</xref>]. The region comprising the Munc13 homology domains is essential for the localization of UNC13D to secretory lysosomes [<xref ref-type="bibr" rid="hlh.REF.neeft.2005.731">Neeft et al 2005</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic variants in <italic toggle="yes">UNC13D</italic> prevent interaction with RAB27A and abolish cytolytic secretion [<xref ref-type="bibr" rid="hlh.REF.neeft.2005.731">Neeft et al 2005</xref>]. Individuals with <italic toggle="yes">UNC13D</italic> pathogenic variants have impaired lymphocyte cytotoxic function with normal or increased perforin expression. Interestingly, the c.118-308C&#x0003e;T pathogenic variant impairs transcription in lymphocytes, but not some other cell types [<xref ref-type="bibr" rid="hlh.REF.meeths.2011.5783">Meeths et al 2011</xref>].</p>
        <table-wrap id="hlh.T.selected_unc13d_pathogenic_allelic" position="anchor" orientation="portrait">
          <label>Table 4. </label>
          <caption>
            <p>Selected <italic toggle="yes">UNC13D</italic> Pathogenic Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hlh.T.selected_unc13d_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_hlh.T.selected_unc13d_pathogenic_allelic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_hlh.T.selected_unc13d_pathogenic_allelic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hlh.T.selected_unc13d_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.118-308C&#x0003e;T</td>
                <td headers="hd_h_hlh.T.selected_unc13d_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                <td headers="hd_h_hlh.T.selected_unc13d_pathogenic_allelic_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_199242.2">NM_199242.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_954712.1">NP_954712.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_unc13d_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">(253-kb inversion)</td>
                <td headers="hd_h_hlh.T.selected_unc13d_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn>
              <p>NA = not applicable</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>
          <bold>
            <italic toggle="yes">STX11</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">STX11</italic> consists of two exons. Exon 2 encodes 287 amino acid residues. Genomic DNA of <italic toggle="yes">STX11</italic> spans about 37 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hlh" object-id="hlh.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> To date, three benign variants have been identified [Zhang, unpublished (2010)]; they are highly unlikely to have pathogenic effects on <italic toggle="yes">STX11</italic> protein expression. See <xref ref-type="table" rid="hlh.T.selected_stx11_allelic_variants">Table 5</xref>.</p>
        <p><bold>Pathogenic allelic variants.</bold> A total of nine distinct pathogenic variants have been reported, including in three families in highly consanguineous Turkish/Kurdish FHL4 kindreds. <italic toggle="yes">STX11</italic> pathogenic variants have been found in individuals with FHL from other ethnic backgrounds, albeit at a low frequency [<xref ref-type="bibr" rid="hlh.REF.marsh.2010b.134">Marsh et al 2010b</xref>]. See <xref ref-type="table" rid="hlh.T.selected_stx11_allelic_variants">Table 5</xref>. Pathogenic nonsense and missense <italic toggle="yes">STX11</italic> variants have been reported in most affected individuals to date. A whole-gene deletion in <italic toggle="yes">STX11</italic> has been reported [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2005.827">zur Stadt et al 2005</xref>].</p>
        <table-wrap id="hlh.T.selected_stx11_allelic_variants" position="anchor" orientation="portrait">
          <label>Table 5. </label>
          <caption>
            <p>Selected <italic toggle="yes">STX11</italic> Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference<break/>Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.146G&#x0003e;A</td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg49Gln</td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_4" rowspan="5" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/187423911">NM_003764.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/33667038">NP_003755.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.546G&#x0003e;A</td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Glu182Gln</td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.651G&#x0003e;T</td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu217Leu</td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.[369_370delAG; 374_379delCGC]<break/>(5-bp deletion)</td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val124GlyfsTer60</td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.802C&#x0003e;T</td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln268Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">g.25560_44750del <break/>(19.2-kb deletion)</td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                <td headers="hd_h_hlh.T.selected_stx11_allelic_variants_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/12666200">AL135917</ext-link>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The gene product of <italic toggle="yes">STX11</italic> is known for its function in vesicle transport. It is a member of soluble N-ethylmaleimide sensitive factor attachment protein receptors present on target membranes (t-SNAREs) [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2005.827">zur Stadt et al 2005</xref>]. STX11 is expressed in peripheral mononuclear cells, as well as in unstimulated NK cells and CD8+ T cells [<xref ref-type="bibr" rid="hlh.REF.bryceson.2007.1906">Bryceson et al 2007</xref>].</p>
        <p><bold>Abnormal gene product.</bold> The absence of the STX11 protein has been observed in monocytes and lymphocytes in persons with FHL4. The abrogation of degranulation and cytotoxicity by resting PBLs observed in this disorder are believed to be caused by the defects in <italic toggle="yes">STX11</italic> [<xref ref-type="bibr" rid="hlh.REF.arneson.2007.3397">Arneson et al 2007</xref>].</p>
        <p>
          <bold>
            <italic toggle="yes">STXBP2</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">STXBP2</italic> is located on chromosome 19p13.3-p13.2 and its genomic DNA spans about 11 kb. <italic toggle="yes">STXBP2</italic> comprises 19 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hlh" object-id="hlh.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> To date, more than two dozen benign variants have been identified [Zhang, unpublished (2012)]; they are highly unlikely to have pathogenic effects on STXBP2 protein expression. For example, the benign variant <xref ref-type="table" rid="hlh.T.selected_stxbp2_allelic_variants">p.Ala433Val</xref> did not affect binding between syntaxin-11 and UNC13B [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</xref>].</p>
        <p><bold>Pathogenic allelic variants.</bold> To date, 27 pathogenic variants have been identified throughout the entire coding region and the exon/intron boundaries of <italic toggle="yes">STXBP2</italic>. Identified variants include pathogenic missense, nonsense, and splice site variants as well as small deletions and/or insertions. Gross deletions, insertions, and other complex variants have not been observed to date [Zhang, unpublished (2012)].</p>
        <table-wrap id="hlh.T.selected_stxbp2_allelic_variants" position="anchor" orientation="portrait">
          <label>Table 6. </label>
          <caption>
            <p>Selected <italic toggle="yes">STXBP2</italic> Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1298C&#x0003e;T</td>
                <td headers="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala433Val</td>
                <td headers="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_4" rowspan="2" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_006949.2">NM_006949.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_008880.2">NP_008880.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1247-1G&#x0003e;C</td>
                <td headers="hd_h_hlh.T.selected_stxbp2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.NA = not applicable</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">STXBP</italic>2 encodes syntaxin-11, a polypeptide of 593 amino acids and a member of the STXBP/Munc-18/Sec1 family. Syntaxin-11, formerly known as UNC18B, is expressed predominantly as a 2.4-kb message in placenta, lung, liver, kidney, and pancreas, as well as in peripheral blood lymphocytes [<xref ref-type="bibr" rid="hlh.REF.ziegler.1996.19">Ziegler et al 1996</xref>]. It interacts with soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) syntaxins, and regulates intracellular vesicle trafficking [<xref ref-type="bibr" rid="hlh.REF.c_te.2009.3765">C&#x000f4;te et al 2009</xref>]. Like other Sec/Munc18 family members, <italic toggle="yes">STXBP2</italic> has three domains and forms an arch-shaped structure. The central cavity, formed by domains 1 and 3a, provide the binding surface for syntaxin-11. In addition, <italic toggle="yes">STXBP2</italic> and <italic toggle="yes">STX11</italic> share binding sites and are colocalized in CD8+ T and NK cells. Stimulation with IL2 can further enhance colocalization in CD8+ and NK cells [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</xref>].</p>
        <p><bold>Abnormal gene product.</bold>
<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2009.482">zur Stadt et al [2009]</xref> showed that missense variants in <italic toggle="yes">STXBP2</italic> can lead to a complete loss of the ability to bind to syntaxin-11. Cultured NK cells from patients with pathogenic variants in <italic toggle="yes">STXBP2</italic> exhibit impaired cytotoxic granule exocytosis with decreased or absent CD107 expression. <italic toggle="yes">Ex vivo</italic> cytotoxicity in NK and cytotoxic T-cell were both decreased [<xref ref-type="bibr" rid="hlh.REF.meeths.2010b.2635">Meeths et al 2010b</xref>]. However, degranulation and cytotoxicity could be at least partially corrected by in vitro stimulation with IL2 [<xref ref-type="bibr" rid="hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</xref>]. Defects in <italic toggle="yes">STXBP2</italic> can reduce or completely abolish syntaxin-11 expression. In contrast, STXBP2 expression does not require syntaxin-11 [<xref ref-type="bibr" rid="hlh.REF.c_te.2009.3765">C&#x000f4;te et al 2009</xref>].</p>
      </sec>
      <sec id="hlh.References">
        <title>References</title>
        <sec id="hlh.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="hlh.Literature_Cited.reflist0">
            <ref id="hlh.REF.allen.2001.499">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Fusco</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legrand</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clementi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conter</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Familial hemophagocytic lymphohistiocytosis: how late can the onset be?</article-title>
                <source>Haematologica.</source>
                <year>2001</year>
                <volume>86</volume>
                <fpage>499</fpage>
                <lpage>503</lpage>
                <pub-id pub-id-type="pmid">11410413</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.aric_.1996.197">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanche</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elinder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinetti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rusca</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society.</article-title>
                <source>Leukemia.</source>
                <year>1996</year>
                <volume>10</volume>
                <fpage>197</fpage>
                <lpage>203</lpage>
                <pub-id pub-id-type="pmid">8637226</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.arneson.2007.3397">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arneson</surname>
                    <given-names>LN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brickshawana</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segovis</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoon</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dick</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leibson</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Cutting edge: syntaxin 11 regulates lymphocyte-mediated secretion and cytotoxicity.</article-title>
                <source>J Immunol.</source>
                <year>2007</year>
                <volume>179</volume>
                <fpage>3397</fpage>
                <lpage>401</lpage>
                <pub-id pub-id-type="pmid">17785771</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.bryceson.2007.1906">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bryceson</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudd</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edner</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ma</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bechensteen</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boelens</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Celkan</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farah</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hultenby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winiarski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roche</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Long</surname>
                    <given-names>EO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ljunggren</surname>
                    <given-names>HG</given-names>
                  </name>
                </person-group>
                <article-title>Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients.</article-title>
                <source>Blood.</source>
                <year>2007</year>
                <volume>110</volume>
                <fpage>1906</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">17525286</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.busiello.2006.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Busiello</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fimiani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miano</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ursini</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignata</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>A91V perforin variation in healthy subjects and FHLH patients.</article-title>
                <source>Int J Immunogenet.</source>
                <year>2006</year>
                <volume>33</volume>
                <fpage>123</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16611257</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.cannella.2007.2566">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cannella</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pillon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mussolin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mangili</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosolen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma.</article-title>
                <source>Cancer.</source>
                <year>2007</year>
                <volume>109</volume>
                <fpage>2566</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">17477373</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.chia.2009.9809">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chia</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeo</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whisstock</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunstone</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trapani</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voskoboinik</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <year>2009</year>
                <volume>106</volume>
                <fpage>9809</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">19487666</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.clementi.2002.2266">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clementi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emmi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maccario</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liotta</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f3;</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations.</article-title>
                <source>Blood.</source>
                <year>2002</year>
                <volume>100</volume>
                <fpage>2266</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12229880</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.clementi.2005.4424">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clementi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Locatelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupr&#x000e9;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garaventa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emmi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bregni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cefalo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pession</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramenghi</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maccario</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncarolo</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <article-title>A proportion of patients with lymphoma may harbor mutations of the perforin gene.</article-title>
                <source>Blood.</source>
                <year>2005</year>
                <volume>105</volume>
                <fpage>4424</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15728124</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.clementi.2001.643">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clementi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>zur Stadt</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savoldi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varoitto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conter</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Fusco</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klersy</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis.</article-title>
                <source>J Med Genet.</source>
                <year>2001</year>
                <volume>38</volume>
                <fpage>643</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11565555</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.c_te.2009.3765">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>C&#x000f4;te</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e9;nager</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgess</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahlaoui</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaffner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Manjomi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Harbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alangari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gennery</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prince</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cariou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nitschke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blank</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Ghazali</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e9;nasch&#x000e9;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells.</article-title>
                <source>J Clin Invest.</source>
                <year>2009</year>
                <volume>119</volume>
                <fpage>3765</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">19884660</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.donn.2008.869">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donn</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellison</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamb</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Day</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baildam</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramanan</surname>
                    <given-names>AV</given-names>
                  </name>
                </person-group>
                <article-title>Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis.</article-title>
                <source>Arthritis Rheum.</source>
                <year>2008</year>
                <volume>58</volume>
                <fpage>869</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">18311812</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.duval.1999.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Duval</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenneteau</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doireau</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faye</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emilie</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yotnda</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drapier</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlegel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sterkers</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Baulny</surname>
                    <given-names>HO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilmer</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance.</article-title>
                <source>J Pediatr.</source>
                <year>1999</year>
                <volume>134</volume>
                <fpage>236</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9931537</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.feldmann.2002.965">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feldmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouach&#x000e9;e-Chardin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Certain</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alexander</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quartier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haddad</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wulffraat</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casanova</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanche</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis.</article-title>
                <source>Br J Haematol.</source>
                <year>2002</year>
                <volume>117</volume>
                <fpage>965</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">12060139</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.filipovich.2011.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>The expanding spectrum of hemophagocytic lymphohistiocytosis.</article-title>
                <source>Curr Opin Allergy Clin Immunol.</source>
                <year>2011</year>
                <volume>11</volume>
                <fpage>512</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21971331</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.fisman.2000.601">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fisman</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <article-title>Hemophagocytic syndromes and infection.</article-title>
                <source>Emerg Infect Dis.</source>
                <year>2000</year>
                <volume>6</volume>
                <fpage>601</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11076718</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.gokce.2012.92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gokce</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unal</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hismi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gumruk</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coskun</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balta</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cetin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalkanoglu-Sivri</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dursun</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokatl&#x00131;</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Secondary hemophagocytosis in 3 patients with organic acidemia involving propionate metabolism.</article-title>
                <source>Pediatr Hematol Oncol.</source>
                <year>2012</year>
                <volume>29</volume>
                <fpage>92</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21970506</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.g_ransdotter_ericson.2001.590">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000f6;ransdotter Ericson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fadeel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nilsson-Ardnor</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000f6;derh&#x000e4;ll</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samuelsson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;rgey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yalman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000e9;v&#x000e9;sz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egeler</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jahnukainen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storm-Mathiesen</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haraldsson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poole</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2001</year>
                <volume>68</volume>
                <fpage>590</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11179007</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.hadchouel.1985.561">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hadchouel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prieur</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griscelli</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection.</article-title>
                <source>J Pediatr.</source>
                <year>1985</year>
                <volume>106</volume>
                <fpage>561</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">3981309</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.henter.1998.417">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elinder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis.</article-title>
                <source>Hematol Oncol Clin North Am.</source>
                <year>1998</year>
                <volume>12</volume>
                <fpage>417</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">9561910</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.henter.2007.124">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f3;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egeler</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ladisch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClain</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winiarski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.</article-title>
                <source>Pediatr Blood Cancer.</source>
                <year>2007</year>
                <volume>48</volume>
                <fpage>124</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">16937360</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.henter.2002.2367">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samuelsson-Horne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egeler</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elinder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gadner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komp</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ladisch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.</article-title>
                <source>Blood.</source>
                <year>2002</year>
                <volume>100</volume>
                <fpage>2367</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">12239144</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.horne.2005a.622">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maarten Egeler</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gadner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ladisch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Locatelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winiarski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <article-title>Histiocyte Society. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis.</article-title>
                <source>Br J Haematol.</source>
                <year>2005a</year>
                <volume>129</volume>
                <fpage>622</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">15916685</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.horne.2008.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramme</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudd</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wali</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>al-Lamki</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;rgey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yalman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <article-title>Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis.</article-title>
                <source>Br J Haematol.</source>
                <year>2008</year>
                <volume>143</volume>
                <fpage>75</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">18710388</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.horne.2005b.658">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenz</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f6;fstedt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marion Schneider</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance.</article-title>
                <source>Br J Haematol.</source>
                <year>2005b</year>
                <volume>129</volume>
                <fpage>658</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">15916689</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.imashuku.1999.1869">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hibi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sako</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arakawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sotomatsu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kataoka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asami</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kosaka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sano</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Igarashi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maruhashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichimi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawasaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maeda</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanizawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hisakawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyashita</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <article-title>Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society.</article-title>
                <source>Blood.</source>
                <year>1999</year>
                <volume>93</volume>
                <fpage>1869</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">10068659</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.imashuku.2000.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teramura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hibi</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH).</article-title>
                <source>Leuk Lymphoma.</source>
                <year>2000</year>
                <month>Sep</month>
                <volume>39</volume>
                <fpage>37</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">10975382</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.imashuku.2005.315">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teramura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mori</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morimoto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sako</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Occurrence of haemophagocytic lymphohistiocytosis at less than 1 year of age: analysis of 96 patients.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2005</year>
                <volume>164</volume>
                <fpage>315</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15731905</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.ishii.2005.3442">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shirakawa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horiuchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohga</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furuno</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morimoto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imayoshi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaitsu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sako</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koike</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasazuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasukawa</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions.</article-title>
                <source>Blood.</source>
                <year>2005</year>
                <volume>105</volume>
                <fpage>3442</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15632205</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.janka.1998.435">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elinder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <article-title>Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis.</article-title>
                <source>Hematol Oncol Clin North Am.</source>
                <year>1998</year>
                <month>Apr</month>
                <volume>12</volume>
                <fpage>435</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">9561911</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.johnson.2010">
              <mixed-citation publication-type="confproc">Johnson J, Kissell D, Huizenga K, Filipovich A, Jordan M, Zur Stadt U, Zhang K. STXBP2 (Munc18) mutations in North American patients with familial hemophagocytic lymphohistiocytosis. Abstract. Montr&#x000e9;al, Quebec, Canada: ASPHO 23rd Annual Meeting, 2010.</mixed-citation>
            </ref>
            <ref id="hlh.REF.jordan.2011.4041">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jordan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitzman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClain</surname>
                    <given-names>KL</given-names>
                  </name>
                </person-group>
                <article-title>How I treat hemophagocytic lymphohistiocytosis.</article-title>
                <source>Blood.</source>
                <year>2011</year>
                <volume>118</volume>
                <fpage>4041</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">21828139</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.kapelari.2005.619">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kapelari</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fruehwirth</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heitger</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;nigsrainer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margreiter</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simma</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Offner</surname>
                    <given-names>FA</given-names>
                  </name>
                </person-group>
                <article-title>Loss of intrahepatic bile ducts: an important feature of familial hemophagocytic lymphohistiocytosis.</article-title>
                <source>Virchows Arch.</source>
                <year>2005</year>
                <volume>446</volume>
                <fpage>619</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">15906086</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.kardas.2012.191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kardas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patiroglu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unal</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryceson</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kendirci</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Hemophagocytic syndrome in a 4-month-old infant with biotinidase deficiency.</article-title>
                <source>Pediatr Blood Cancer.</source>
                <year>2012</year>
                <month>Jul</month>
                <day>15</day>
                <volume>59</volume>
                <fpage>191</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">22605457</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.katano.2004.1244">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Katano</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ali</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patera</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catalfamo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaffe</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dale</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straus</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <article-title>Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation.</article-title>
                <source>Blood.</source>
                <year>2004</year>
                <volume>103</volume>
                <fpage>1244</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">14576041</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.lee.2006.134">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumegi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villanueva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakraborty</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheng</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clementi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50delT mutation.</article-title>
                <source>J Pediatr.</source>
                <year>2006</year>
                <volume>149</volume>
                <fpage>134</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16860143</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.ma.2001.358">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ma</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yosioka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishiguro</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kikuta</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>K.</given-names>
                  </name>
                </person-group>
                <article-title>No mutations of SAP/SH2D1A/DSHP and perforin genes in patients with Epstein-Barr virus-associated hemophagocytic syndrome in Japan.</article-title>
                <source>J Med Virol.</source>
                <year>2001</year>
                <volume>65</volume>
                <fpage>358</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">11536244</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.malloy.2004.458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malloy</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polinski</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alkan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manera</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Challapalli</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Hemophagocytic lymphohistiocytosis presenting with nonimmune hydrops fetalis.</article-title>
                <source>J Perinatol.</source>
                <year>2004</year>
                <volume>24</volume>
                <fpage>458</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">15224121</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.marcenaro.2006.2316">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marcenaro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f3;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pende</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease.</article-title>
                <source>Blood.</source>
                <year>2006</year>
                <volume>108</volume>
                <fpage>2316</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">16778144</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.marcoux.2005.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marcoux</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laporte-Turpin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberge</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fournie-Gardini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castex</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brivet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broue</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Congenital galactosaemia: an unusual presentation.</article-title>
                <source>Arch Pediatr.</source>
                <year>2005</year>
                <volume>12</volume>
                <fpage>160</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">15694540</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.marsh.2010a.1079">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madden</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitchen</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mody</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClimon</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jordan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleesing</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease.</article-title>
                <source>Blood.</source>
                <year>2010a</year>
                <volume>116</volume>
                <fpage>1079</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">20489057</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.marsh.2010b.134">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satake</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biroschak</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobs</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jordan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleesing</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America.</article-title>
                <source>Pediatr Blood Cancer.</source>
                <year>2010b</year>
                <volume>55</volume>
                <fpage>134</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">20486178</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.marsh.2010c.5824">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaughn</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jodele</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joshi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jordan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleesing</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.</article-title>
                <source>Blood.</source>
                <year>2010c</year>
                <volume>116</volume>
                <fpage>5824</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">20855862</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.meeths.2010a.563">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meeths</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryceson</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudd</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramme</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heilmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hultenby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ljunggren</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fadeel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <article-title>Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations.</article-title>
                <source>Pediatr Blood Cancer.</source>
                <year>2010a</year>
                <volume>54</volume>
                <fpage>563</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">19953648</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.meeths.2010b.2635">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meeths</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Entesarian</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Herz</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Ateeqi</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almazan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boelens</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ifversen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lund</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gustafsson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjelmqvist</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryceson</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <article-title>Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2.</article-title>
                <source>Blood.</source>
                <year>2010b</year>
                <volume>116</volume>
                <fpage>2635</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">20558610</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.meeths.2011.5783">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meeths</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Entesarian</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlums</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bj&#x000f6;rklund</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakovljevic</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jazbec</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmqvist</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rajic</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfeifer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosth&#x000f8;j</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salmi</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stokland</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winiarski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ljunggren</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fadeel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryceson</surname>
                    <given-names>YT</given-names>
                  </name>
                </person-group>
                <article-title>Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D.</article-title>
                <source>Blood.</source>
                <year>2011</year>
                <volume>118</volume>
                <fpage>5783</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">21931115</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.m_nager.2007.473">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>M&#x000e9;nager</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Secretory cytotoxic granule maturation is required to their lytic contents excretion.</article-title>
                <source>Med Sci (Paris)</source>
                <year>2007</year>
                <volume>23</volume>
                <fpage>473</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17502060</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.m_nager.2007.257">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>M&#x000e9;nager</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e9;nasch&#x000e9;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romao</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knapnougel</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garfa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raposo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4.</article-title>
                <source>Nat Immunol.</source>
                <year>2007</year>
                <volume>8</volume>
                <fpage>257</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">17237785</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.m_nasch_.2005.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>M&#x000e9;nasch&#x000e9;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis.</article-title>
                <source>Immunol Rev.</source>
                <year>2005</year>
                <volume>203</volume>
                <fpage>165</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">15661029</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.m_nasch_.2000.173">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>M&#x000e9;nasch&#x000e9;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastural</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Certain</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ersoy</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupuis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wulffraat</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianchi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome.</article-title>
                <source>Nat Genet.</source>
                <year>2000</year>
                <volume>25</volume>
                <fpage>173</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10835631</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.molleran_lee.2004.137">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Molleran Lee</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villanueva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumegi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kogawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis.</article-title>
                <source>J Med Genet.</source>
                <year>2004</year>
                <volume>41</volume>
                <fpage>137</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">14757862</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.muiesan.1998.794">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Muiesan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dhawan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mufti</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Grady</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rela</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heaton</surname>
                    <given-names>ND</given-names>
                  </name>
                </person-group>
                <article-title>Hemophagocytosis: a potential complication in small bowel transplantation.</article-title>
                <source>Transplantation.</source>
                <year>1998</year>
                <volume>66</volume>
                <fpage>794</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9771844</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.neeft.2005.731">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neeft</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieffer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Jong</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Negroiu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metz</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Loon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffith</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krijgsveld</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wulffraat</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heck</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brose</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleijmeer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Sluijs</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells.</article-title>
                <source>Mol Biol Cell.</source>
                <year>2005</year>
                <volume>16</volume>
                <fpage>731</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">15548590</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.nitta.2007.98">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nitta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzumura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watabe</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okuya</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakajima</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurosawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugita</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arisaka</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Fetal hemophagocytic lymphohistiocytosis in a premature infant.</article-title>
                <source>J Pediatr.</source>
                <year>2007</year>
                <volume>151</volume>
                <fpage>98</fpage>
                <pub-id pub-id-type="pmid">17586201</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.normand.2000.5406">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Normand</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehman</surname>
                    <given-names>TJA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elkon</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onel</surname>
                    <given-names>KB</given-names>
                  </name>
                </person-group>
                <article-title>Lower expression of perforin in CD8+ T cells of patients with systemic onset juvenile rheumatoid arthritis.</article-title>
                <source>Arthritis Rheum.</source>
                <year>2000</year>
                <volume>43</volume>
                <fpage>5406</fpage>
              </element-citation>
            </ref>
            <ref id="hlh.REF.ohadi.1999.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ohadi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalloz</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sham</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dearlove</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiach</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinsey</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhodes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Layton</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1999</year>
                <volume>64</volume>
                <fpage>165</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">9915955</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.orilieri.2008.1078">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orilieri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappellano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clementi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cometa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferretti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerutti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cadario</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinetti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larizza</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calcaterra</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Annunzio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerutti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiocchetti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dianzani</surname>
                    <given-names>U.</given-names>
                  </name>
                </person-group>
                <article-title>Variations of the perforin gene in patients with type 1 diabetes.</article-title>
                <source>Diabetes.</source>
                <year>2008</year>
                <volume>57</volume>
                <fpage>1078</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">18198357</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.pachlopnik_schmid.2011.1522">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pachlopnik Schmid</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canioni</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moshous</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touzot</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahlaoui</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hauck</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanegane</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez-Granados</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mejstrikova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellier</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galicier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galambrun</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlogis</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordigoni</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fourmaintraux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamidou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dabadie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haerynck</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouach&#x000e9;e-Chardin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohrlich</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephan</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rigaud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milili</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiff</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanche</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latour</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency).</article-title>
                <source>Blood.</source>
                <year>2011</year>
                <volume>117</volume>
                <fpage>1522</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21119115</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.pagel.2012.6016">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pagel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehmberg</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maul-Pavicic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohlfs</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Jefri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beier</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bomme Ousager</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehlert</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross-Wieltsch</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jorch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremens</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pekrun</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sparber-Sauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mejstrikova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wawer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>zur Stadt</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5).</article-title>
                <source>Blood.</source>
                <year>2012</year>
                <volume>119</volume>
                <fpage>6016</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">22451424</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.rigaud.2006.110">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rigaud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fondan&#x000e8;che</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mateo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soulas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galicier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rieux-Laucat</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Revy</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latour</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome.</article-title>
                <source>Nature.</source>
                <year>2006</year>
                <volume>444</volume>
                <fpage>110</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17080092</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.rudd.2006.e14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rudd</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f6;ransdotter Ericson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uysal</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozkan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;rgey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fadeel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <article-title>Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies.</article-title>
                <source>J Med Genet.</source>
                <year>2006</year>
                <volume>43</volume>
                <fpage>e14</fpage>
                <pub-id pub-id-type="pmid">16582076</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.shah.2009.139">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kapoor</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crooks</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenarsky</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdel-Azim</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>SQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinberg</surname>
                    <given-names>KI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parkman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohn</surname>
                    <given-names>DB</given-names>
                  </name>
                </person-group>
                <article-title>Pre- and post-natal treatment of hemophagocytic lymphohistiocytosis.</article-title>
                <source>Pediatr Blood Cancer.</source>
                <year>2009</year>
                <volume>52</volume>
                <fpage>139</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">18819128</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.shuper.1998.126">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shuper</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Attias</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornreich</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaizov</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaniv</surname>
                    <given-names>I.</given-names>
                  </name>
                </person-group>
                <article-title>Familial hemophagocytic lymphohistiocytosis: improved neurodevelopmental outcome after bone marrow transplantation.</article-title>
                <source>J Pediatr.</source>
                <year>1998</year>
                <volume>133</volume>
                <fpage>126</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9672524</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.sieni.2012a.29">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sieni</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cetica</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mastrodicasa</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pende</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Familial hemophagocytic lymphohistiocytosis: a model for understanding the human machinery of cellular cytotoxicity.</article-title>
                <source>Cell Mol Life Sci.</source>
                <year>2012a</year>
                <volume>69</volume>
                <fpage>29</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">21990010</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.sieni.2012b.e44649">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sieni</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cetica</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piccin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gherlinzoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasso</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabusin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Attard</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pende</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series.</article-title>
                <source>PLoS One.</source>
                <year>2012b</year>
                <volume>7</volume>
                <fpage>e44649</fpage>
                <pub-id pub-id-type="pmid">22970278</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.solomou.2007.5234">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Solomou</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibellini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malide</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visconte</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Childs</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanock</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>NS</given-names>
                  </name>
                </person-group>
                <article-title>Perforin gene mutations in patients with acquired aplastic anemia.</article-title>
                <source>Blood.</source>
                <year>2007</year>
                <volume>109</volume>
                <fpage>5234</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17311987</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.st_phan.1993.451">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>St&#x000e9;phan</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeller</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hubert</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herbelin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dayer</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prieur</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <article-title>Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases.</article-title>
                <source>Clin Exp Rheumatol.</source>
                <year>1993</year>
                <volume>11</volume>
                <fpage>451</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8403593</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.stepp.1999.1957">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stepp</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufourcq-Lagelouse</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhawan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Certain</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathew</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Perforin gene defects in familial hemophagocytic lymphohistiocytosis.</article-title>
                <source>Science.</source>
                <year>1999</year>
                <volume>286</volume>
                <fpage>1957</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10583959</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.sung.2002.550">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sung</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carcao</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trebo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitzman</surname>
                    <given-names>SS</given-names>
                  </name>
                </person-group>
                <article-title>Adverse outcomes in primary hemophagocytic lymphohistiocytosis.</article-title>
                <source>J Pediatr Hematol Oncol.</source>
                <year>2002</year>
                <volume>24</volume>
                <fpage>550</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12368693</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.trambas.2005.932">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trambas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pende</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcenaro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Fusco</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arico</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <article-title>A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin.</article-title>
                <source>Blood.</source>
                <year>2005</year>
                <volume>106</volume>
                <fpage>932</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15741215</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.trizzino.2008.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trizzino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>zur Stadt</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Risma</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumegi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cannella</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pende</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mian</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aric&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                  <collab>Histiocyte Society HLH Study group</collab>
                </person-group>
                <article-title>Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations.</article-title>
                <source>J Med Genet.</source>
                <year>2008</year>
                <volume>45</volume>
                <fpage>15</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">17873118</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.ueda.2006.179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kashiwamura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekiyama</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gamachi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamura</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Production of IL-13 in spleen cells by IL-18 and IL-12 through generation of NK-like cells.</article-title>
                <source>Cytokine.</source>
                <year>2006</year>
                <volume>33</volume>
                <fpage>179</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">16549365</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.villanueva.2005.r30">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Villanueva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giannini</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passo</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grom</surname>
                    <given-names>AA</given-names>
                  </name>
                </person-group>
                <article-title>Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome.</article-title>
                <source>Arthritis Res Ther.</source>
                <year>2005</year>
                <volume>7</volume>
                <fpage>R30</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15642140</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.voskoboinik.2007.1184">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Voskoboinik</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sutton</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciccone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>House</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chia</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darcy</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yagita</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trapani</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function.</article-title>
                <source>Blood.</source>
                <year>2007</year>
                <volume>110</volume>
                <fpage>1184</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">17475905</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.voskoboinik.2004.811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Voskoboinik</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thia</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Bono</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Browne</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cretney</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darcy</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jane</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smyth</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trapani</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene.</article-title>
                <source>J Exp Med.</source>
                <year>2004</year>
                <volume>200</volume>
                <fpage>811</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15365097</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.voskoboinik.2005.4700">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Voskoboinik</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thia</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trapani</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis.</article-title>
                <source>Blood.</source>
                <year>2005</year>
                <volume>105</volume>
                <fpage>4700</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15755897</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.woods.2009.265">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bradshaw</surname>
                    <given-names>WT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>AG</given-names>
                  </name>
                </person-group>
                <article-title>Hemophagocytic lymphohistiocytosis in the premature neonate.</article-title>
                <source>Adv Neonatal Care.</source>
                <year>2009</year>
                <volume>9</volume>
                <fpage>265</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">20010142</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.yamamoto.2004.763">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sako</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohga</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furuno</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imayoshi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morimoto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasazuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasukawa</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Identification of novel MUNC13-4 mutations in familial haemophagocytic lymphohistiocytosis and functional analysis of MUNC13-4-deficient cytotoxic T lymphocytes.</article-title>
                <source>J Med Genet.</source>
                <year>2004</year>
                <volume>41</volume>
                <fpage>763</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15466010</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.zhang.2011.5794">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jordan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kissell</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meller</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villanueva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Risma</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH.</article-title>
                <source>Blood.</source>
                <year>2011</year>
                <volume>118</volume>
                <fpage>5794</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21881043</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.zhang.2008.2892">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biroschak</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glass</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finkel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passo</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Binstadt</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grom</surname>
                    <given-names>AA</given-names>
                  </name>
                </person-group>
                <article-title>Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms.</article-title>
                <source>Arthritis Rheum.</source>
                <year>2008</year>
                <volume>58</volume>
                <fpage>2892</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18759271</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.zhang.2007.231">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biroschak</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villanueva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleesing</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Risma</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>Familial haemophagocytic lymphohistiocytosis in patients who are heterozygous for the A91V perforin variation is often associated with other genetic defects.</article-title>
                <source>Int J Immunogenet.</source>
                <year>2007</year>
                <volume>34</volume>
                <fpage>231</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">17627755</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.ziegler.1996.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortrud</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swartz</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sutherland</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burmeister</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulligan</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Molecular characterization of a nonneuronal human UNC18 homolog.</article-title>
                <source>Genomics.</source>
                <year>1996</year>
                <volume>37</volume>
                <fpage>19</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">8921365</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.zur_stadt.2006.62">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>zur Stadt</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kabisch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennies</surname>
                    <given-names>HC</given-names>
                  </name>
                </person-group>
                <article-title>Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A.</article-title>
                <source>Hum Mutat.</source>
                <year>2006</year>
                <volume>27</volume>
                <fpage>62</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16278825</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.zur_stadt.2009.482">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>zur Stadt</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohr</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seifert</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grieve</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasper</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000fc;rnberg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maul-Pavicic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennies</surname>
                    <given-names>HC</given-names>
                  </name>
                </person-group>
                <article-title>Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2009</year>
                <volume>85</volume>
                <fpage>482</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">19804848</pub-id>
              </element-citation>
            </ref>
            <ref id="hlh.REF.zur_stadt.2005.827">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>zur Stadt</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasper</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diler</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kabisch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000fc;rnberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennies</surname>
                    <given-names>HC</given-names>
                  </name>
                </person-group>
                <article-title>Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2005</year>
                <volume>14</volume>
                <fpage>827</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">15703195</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="hlh.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="hlh.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>17 January 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>7 September 2010 (cd) Revision: sequence analysis of <italic toggle="yes">STXBP2</italic> for familial hemophagocytic lymphohistiocytosis 5 available clinically</p>
            </list-item>
            <list-item>
              <p>11 March 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>9 March 2007 (cd) Revision: clinical testing and prenatal diagnosis available for FHL4</p>
            </list-item>
            <list-item>
              <p>22 March 2006 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>21 April 2005 (jj, af, rw) Original Submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
